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ZUSAMMENFASSUNG FÜR LAIEN 
Eine zentrale Herausforderung aktueller Arzneimittelforschung besteht darin, dass neue und 
vielversprechende Wirkstoffe oft schlecht vom Körper aufgenommen oder schnell wieder abgebaut 
werden. Beides führt dazu, dass hohe Dosen an Wirkstoffen verabreicht werden müssen, um 
therapeutisch wirksam zu sein. Die hohen Dosen resultieren dann in immer stärkeren 
Nebenwirkungen. Um diese Herausforderung zu meistern, verpackt man Wirkstoffe häufig in 
Transportsysteme, welche den Wirkstoff an den Zielort bringen, und ihn vor vorzeitigem Abbau im 
Körper schützen. Solche Transportsysteme bestehen oft aus Polymeren und können ganz verschiedene 
Formen annehmen. Polymere sind Stoffe, die aus vielen sich wiederholenden Untereinheiten 
bestehen. Diese Untereinheiten können sowohl immer die gleichen sein, oder sich auch voneinander 
unterscheiden. Die Anzahl der Untereinheiten ist ebenfalls variabel. Es gibt natürliche Polymere, die in 
Lebewesen synthetisiert werden und daher auch Biopolymere genannt werden. Synthetische 
Polymere hingegen werden künstlich hergestellt oder entstehen bei der chemischen 
Weiterverarbeitung von Biopolymeren.  
Ein erster Ansatz, Wirkstoffe an ihren Zielort zu transportieren, besteht darin, sie in winzig kleine 
Transportsysteme, so genannte Nanopartikel, zu packen. Nanopartikel sind so klein, dass man davon 
1’000 bis 1'000'000 aneinanderreihen müsste, um einen Millimeter an Strecke zurückzulegen. Wir 
haben solche Nanopartikel aus synthetischen Polymerketten hergestellt und ihre Oberfläche so 
bearbeitet, dass sie ganz bestimmte Leberzellen (Hepatozyten) erkennen. Vereinfacht funktioniert das 
wie ein Schlüssel, der in ein dazugehöriges Schloss passt. Ein bestimmtes Protein an der Oberfläche 
eines Nanopartikels (quasi der Schlüssel) kann diesen an eine dazu passende Zelle andocken lassen, 
die sozusagen das Schloss, also den entsprechenden Rezeptor, vorweist. In Zellexperimenten konnten 
wir demonstrieren, dass solche modifizierten Nanopartikel besser von den passenden Zellen 
aufgenommen wurden als Nanopartikel, die keine modifizierte Oberfläche – also keinen passenden 
Schlüssel – hatten. Wir konnten ausserdem zeigen, dass solche Nanopartikel für unsere Zellen nicht 
giftig waren und bestätigten dies in ersten Versuchen mit Zebrafisch Embryos. Zebrafische sind ein 
sehr interessantes Tiermodell für die Arzneimittelentwicklung, da ihr Erbgut dem des Menschen relativ 
ähnlich ist. Zudem entwickeln sich die Embryos innerhalb weniger Tage – und das auch noch 
ausserhalb des Mutterleibs, im Gegensatz zu klassischen Labortieren wie Mäusen und Ratten. Man 
kann also die Embryonalentwicklung dieser Tiere sehr gut beobachten, was sie besonders für das 
Testen potenziell giftiger Substanzen interessant macht. Doch selbst wenn man herausfindet, dass eine 
Formulierung in Zebrafischen gut vertragen wird, ist es bisher nicht möglich, komplett auf weitere 
Tierversuche zu verzichten. Die potenziellen neuen Medikamente müssen noch einen langen Weg an 
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Tierversuchen und weiteren Charakterisierungen durchlaufen, bevor man sie für sicher genug 
erachtet, um sie das erste Mal an Menschen zu testen. Zebrafische bilden also quasi eine 
Zwischenstufe, um die nachfolgenden Tierversuche auf ein Minimum reduzieren zu können. 
 
Als weiteres Transportsystem für Wirkstoffe haben wir aus Polymeren Hydrogele hergestellt. Diese 
bestehen aus miteinander verknüpften Polymerketten und wenn man sie stark vergrössert betrachtet, 
kann man eine netzartige Struktur erkennen. Je nach Ausgangsstoffen und Herstellungsmethode sind 
solche Hydrogele unterschiedlich stabil und haben unterschiedlich grosse Poren. Generell sind sie 
dadurch charakterisiert, dass sie grosse Mengen an Flüssigkeit aufnehmen und auch wieder abgeben 
können, weshalb sie gerne als Wundauflagen verwendet werden. Diese dürfen die Wunde nicht noch 
zusätzlich reizen, sondern sollen gut verträglich und ungiftig sein. Des Weiteren sollte das Material des 
Wundverbandes nicht mit der Wunde verkleben und ein feuchtes Wundmilieu schaffen, das 
heilungsfördernd ist.  
Ein Polymer, das für solche Wundauflagen geeignet ist, heisst Chitosan. Chitosan ist ein natürliches 
Material, das unter anderem in der Schale von Krebstieren und den Zellwänden von Pilzen vorkommt. 
Wir haben Chitosan auf zwei verschiede Arten chemisch verändert. Beim Mischen dieser beiden 
unterschiedlich modifizierten Polymere bildete sich ein Gel. Wir konnten ein Protein in dieses Gel laden 
und zeigen, dass es verzögert auch wieder freigesetzt wurde. Dahinter steht die Idee, eine 
Wundauflage zu schaffen, die alle Substanzen in sich vereint, welche der Körper für die Wundheilung 
benötigt. Das sind zum Beispiel Stoffe, die die Neubildung von Blutgefässen oder frischen Hautzellen 
fördern. Insbesondere Patienten mit chronischen Wunden könnten von solchen Verbandsmaterialien 
profitieren, da ihre körpereigene Wundheilung aus verschiedensten Gründen gestört ist. Ein weiterer 
Vorteil des Gels, das wir hergestellt haben, ist die Möglichkeit, es gefrierzutrocknen. Gefriertrocknung 
ist ein Prozess zur schonenden Trocknung von Stoffen, ohne diese erhitzen zu müssen. Typische 
Beispiele aus dem Alltag sind Instant-Kaffee oder Früchte in Müslimischungen. Gefriergetrocknete 
Produkte sind wesentlich länger haltbar und einfacher zu transportieren als in ihrer unverarbeiteten 
Form. Unser gefriergetrocknetes Chitosan-Gel hatte eine watteähnliche Konsistenz und konnte durch 
den Kontakt mit Flüssigkeit erfolgreich wieder rehydriert (also gelförmig gemacht) werden. Das ist sehr 
vielversprechend für eine Wundauflage: Das getrocknete Gel könnte zum Beispiel auf eine nässende 
Wunde aufgelegt und luftdicht befestigt werden. Das Wundsekret würde zu einer Rehydrierung des 
Gels führen, die im Gel eingeschlossenen Wirkstoffe aus dem Gel könnten an die Wunde abgegeben 
werden, und die Wunde würde konstant feucht bleiben und könnte dementsprechend gut heilen. 
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Eine weitere Anwendungsmöglichkeit für Polymere als Wirkstoffträger sind dünne Filme/Membranen, 
die in den Mund genommen werden und sich dort innerhalb kurzer Zeit auflösen. Solche Filme sind 
maximal briefmarkengross und werden entweder auf die Zunge, unter die Zunge, in die Backentasche 
oder an den Gaumen geklebt. Dort lösen sie sich schnell auf und geben ihren Wirkstoff frei. Für 
Patienten sind solche Filme sehr angenehm, da sie nicht geschluckt werden müssen und deshalb 
einfach einzunehmen sind. Das ist vor allem für Menschen mit Schluckschwierigkeiten, wie Kinder oder 
ältere Patienten, relevant.  
Wir haben einen solchen speziellen Film in einer klinischen Studie getestet. Dieser Film enthält winzige 
Mengen an Midazolam. Das ist eigentlich ein Schlaf- und Beruhigungsmittel. Es kann aber auch 
verwendet werden, um zu bestimmen, wie gut ein bestimmter Medikamenten-Abbaumechanismus 
bei einzelnen Patienten funktioniert. Der hier untersuchte Abbauweg wird durch das sogenannte 
Enzym CYP3A gesteuert und ist für mehr als 50% der handelsüblichen Medikamente relevant. Deshalb 
ist er auch anfällig für Wechselwirkungen: Einzelne Medikamente oder auch andere Substanzen (z.B. 
Grapefruitsaft) können ihn nämlich hemmen oder verstärken, so dass parallel verabreichte 
Medikamente viel langsamer oder schneller abgebaut werden als man das erwarten würde. 
Vernachlässigt man das bei der Verabreichung von Arzneimitteln, kann es für den Patienten zu 
gefährlichen Unter- oder Überdosierungen kommen. Eine Überprüfung dieser Enzymaktivität nennt 
man Phänotypisierung. Allerdings möchte man natürlich die Patienten bei einer Phänotypisierung mit 
Midazolam nicht jedes Mal sedieren (aufgrund der beruhigenden Eigenschaften von Midazolam), 
sondern nur ganz geringe Mengen davon verwenden. Je geringer jedoch eine verabreichte Menge, 
desto schwieriger ist es, diese genau herzustellen und zu verabreichen. Bisher geht das nur, wenn man 
die Midazolam-Lösung stark verdünnt. Einfacher und reproduzierbarer wäre eine fertige Formulierung, 
die eine solche winzige Dosis Midazolam bereits enthält und direkt verwendet werden kann. Wir 
konnten klinisch zeigen, dass ein Film aus Polymeren geeignet ist, winzige Mengen an Midazolam zu 
transportieren und Aussagen über die Enzymaktivität von CYP3A zu treffen. Insbesondere für die 
Phänotypisierung von Kindern und älteren Patienten wäre das sehr interessant, da die Probe weder 
geschluckt werden muss noch ausgespuckt werden kann. Die daraus resultierende Vereinfachung der 
Phänotypisierung stellt einen wichtigen Meilenstein auf dem Weg zu einem modernen, 
individualisierten und patientenzentrierten Behandlungsansatz dar. Allerdings sind natürlich noch 
viele weitere Untersuchungen nötig. 
 
Eine Alternative für kinderfreundliche Arzneimittelformulierungen sind Tabletten, die bei 
Speichelkontakt schnell im Mund zerfallen. Wie bei den oben beschriebenen Filmen kann man auch 
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mit solchen Tabletten gut dosieren und trotzdem vermeiden, dass grosse Tabletten oder Kapseln 
geschluckt werden müssen. Leider gibt es bis heute nur sehr wenige solcher Formulierungen auf dem 
Markt – und noch weniger davon sind für Kinder zugelassen. Hier besteht also dringend 
Nachholbedarf. Allerdings muss man bei der Entwicklung von kinderfreundlichen Medikamenten 
darauf achten, wie Kinder deren Geschmack empfinden. Oft verweigern sie nämlich die Einnahme 
schlecht-schmeckender Arzneimittel. Das wiederum führt dann zu Therapieabbrüchen und 
unwirksamen Therapien.  
Wir haben daher eine neu entwickelte, schnell-zerfallende Placebo-Tablette (also eine Tablette ohne 
aktiven Wirkstoff) an Kindern getestet. Von Erwachsenen war diese bereits als sehr positiv beurteilt 
worden. Man kann jedoch nicht direkt von Erwachsenen auf Kinder schliessen, da deren Mundgefühl 
und Geschmackssensoren sehr unterschiedlich sind. Darum wurden Kinder zwischen 2 und 10 Jahren 
gebeten, die Tabletten zu probieren. Wir haben dann einerseits beobachtet, wie die Kinder auf die 
Tabletten reagiert haben (z.B. ob sie weinen mussten oder sie direkt wieder ausspuckten) und wie die 
Eltern die Verabreichung bewerten (v.a. im Vergleich zu anderen Medikamenten, die sie bereits 
kennen). Bei den älteren Kindern haben wir ausserdem untersucht, wie schnell die Tablette im Mund 
zerfällt und wo danach Rückstände zu finden sind. Diese Kinder sollten auch bewerten, wie gut ihnen 
die Tablette geschmeckt hat, und ob sie noch eine zweite Tablette nehmen würden. Zusammenfassend 
kann gesagt werden, dass sowohl Kinder wie auch Eltern diese Tablette sehr gut akzeptierten und sehr 
positiv darauf reagierten. Auch Kinder, die sonst keine Tabletten, Kapseln oder flüssigen Arzneimittel 
schlucken wollen/können, fanden unsere Testtablette sehr lecker. Diese Art der Formulierung eröffnet 
also vielversprechende Möglichkeiten: Solche schnell zerfallenden Tabletten könnten als 
Transportsysteme für viele verschiedene Wirkstoffe dienen, die bisher nicht in kindgerechter oder nur 
in schlecht schmeckender flüssiger Form verfügbar sind. 
Zusammenfassend haben wir also verschiedenste innovative, grösstenteils polymerbasierte 
Applikationsformen für arzneiliche Wirkstoffe präklinisch und klinisch evaluiert und wichtige 
Erkenntnisse dazu gewonnen, wie die Wirkstoffverfügbarkeit weiter optimiert werden kann. 
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SUMMARY 
Currently, many promising therapeutic compounds suffer from substantial drawbacks such as rapid 
clearance from circulation, poor bioavailability, or severe toxicity in patients. One option to face these 
challenges might be the usage of nanoparticles as drug delivery systems. There are different classes of 
formulations, so called nanomedicines, including drug-protein conjugates, drug-polymer conjugates, 
liposomes, micelles, and polymersomes. In general, main therapeutic fields for engineered 
nanomaterials are oncology, cardiovascular medicine, neurology, anti-inflammatory drugs, and anti-
infectious treatment.  
Herein (chapter 2.1), polymersomes prepared of the diblock copolymer PDMS-b-PMOXA are 
described. These were synthesised and modified to achieve targeting to the asialoglycoprotein 
receptor of hepatocytes. Conjugation of asialofetuin to the polymersomes’ surface increased uptake 
of these polymersomes into hepatocytes, when compared to unmodified polymersomes. Moreover, a 
model compound was successfully encapsulated into the polymersomes and sustained release was 
achieved. Biocompatibility of the various polymersomes was assessed in vitro, and zebrafish embryos 
were utilised as a first vertebrate model to evaluate in vivo toxicity. In conclusion, the targeted drug 
delivery system was safe and well tolerated in vitro as well as in vivo. Successful drug encapsulation 
and release make it a promising tool for clinical applications in the field of hepatology. Further 
comprehensive investigations, especially regarding scalability of production process and in vivo 
characterisation would be needed before stepping forward to the clinics.  
 
In addition to nanoparticles, polymers can also be used to synthesise hydrogels. Hydrogels are 
crosslinked networks formed by a hydrophilic macromolecular polymer. Their mesh like structure and 
physicochemical properties allow hydrogels to imbibe large amounts of water and to be used as drug 
delivery systems. Therefore, hydrogels are of special interest in the fields of drug delivery, biosensing, 
and tissue engineering.  
In this work (chapter 2.2), a self-assembling chitosan hydrogel based on chemically modified chitosan 
(a natural polymer) was prepared. Chitosan is known to be biocompatible, biodegradable, bio-
renewable, and non-toxic. In addition, it is tissue-regenerating, haemostatic, and immune-stimulating, 
making it a very promising hydrogel scaffold for wound dressing. The obtained self-assembling 
chitosan hydrogel had a porous structure enabling loading it with proteins and releasing them in a 
sustained manner. Moreover, the hydrogel was biodegradable and could be lyophilised. These 
characteristics make it a promising scaffold for application of therapeutic proteins in the treatment of 
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chronic wounds. It remains to be elucidated how this chitosan hydrogel loaded with therapeutic 
proteins would behave in vitro as well as in vivo before clinical applications could be considered. 
 
Another application for polymers are buccal films (BFs). BFs can be loaded with drugs and enable oral 
absorption of these drugs upon placing the BFs into the oral cavity, either sublingual, buccal, or palatal. 
Besides fast onset of action and reduced first pass metabolism, BFs are easy to be administered, even 
to vulnerable patient populations such as geriatric or paediatric patients who have difficulties with 
swallowing liquid or solid oral dosage formulations. This makes BFs – amongst other potential 
applications – highly valuable for phenotyping purposes, especially for these patient groups. 
Phenotyping is particularly important for drugs with a narrow therapeutic window that need to be 
carefully dosed, based on the patient’s individual metabolic capacity. One main metabolising enzyme 
is cytochrome P450 3A (CYP3A). It is assumed that CYP3A is involved in the metabolism of more than 
50% of the marketed drugs. Consequently, such an essential metabolism pathway will be frequently 
affected by various drug-drug interactions including either inhibition of CYP3A enzymes or increase of 
CYP3A expression. Enzyme activity can vary up to 400-fold and thus, plasma concentrations of 
co-administered drugs can change tremendously resulting in either reduced drug activity or toxic side 
effects. To phenotype CYP3A, the benzodiazepine midazolam is a well-accepted probe drug, but 
suffering from the drawback that patients are sedated during phenotyping with pharmacologically 
active midazolam doses. Therefore, a microdosing approach for phenotyping was recently developed. 
One elegant option to formulate and administer microdoses are BFs.  
Herein (chapter 2.3), a clinical study investigating the usability of a microdosed midazolam BF for 
phenotyping is described. According to the outcomes, such a film can be considered an interesting 
novel diagnostic tool in the field of personalised medicine. Before making its step into clinical daily 
practice, it remains to be evaluated how the microdosed midazolam BF reflects increased or inhibited 
CP3A activity. Moreover, it would be necessary to test the film again in a greater variety of volunteers 
(e.g. different age or weight) to be able to generalise the results obtained from the former study. 
 
As mentioned above, paediatric patients are a vulnerable population with the need for oral 
formulations that are easy and safe to administer. A medication’s taste and the ability of children to 
swallow their medicine may greatly influence the selection of a drug, therefore therapy and prescribing 
practice. The medication palatability is essential for patient acceptance, therapeutic compliance and 
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successful outcome of a therapy. Not only BFs but also oral disintegrating tablets (ODTs) offer great 
options for this purpose. 
To test the palatability of a placebo ODT based on Functionalised Calcium Carbonate, a clinical study 
with 40 children from 2 to 10 years was conducted, in a setup that considered the specific 
communication challenges with this target group – obviously children cannot be expected to give 
quantified feedback on likeability, taste, etc. (chapter 2.4). The tablet was highly accepted by children 
as well as by their parents. Such palatable, inert carrier ODTs could be formulated to contain a wide 
range of active pharmaceutical ingredients for oral delivery that are currently unavailable as child 
friendly formulations or exist only as bad tasting liquids. This includes frequently used and highly 
relevant drugs, such as antibiotics and steroids. Therefore, the tested ODT or similar child-appropriate 
solid oral dosage forms could improve world-wide access to high quality medicines and adherence for 
children in future. 
In summary, a broad variety of innovative, mostly polymer-based application forms for drug 
ingredients have been preclinically and clinically evaluated and led to relevant insights on how drug 
availability could be further optimised. 
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AIM OF THE THESIS 
At first, the synthetic diblock copolymer PDMS-b-PMOXA was used to synthesise polymersomes. This 
included: 
 Characterisation of their physicochemical properties: size, surface charge, stability in serum, 
loading capacity and release characteristics, and in vitro and early in vivo biocompatibility. 
 Chemical surface modification with asialofetuin to target the asialoglycoprotein receptor of 
hepatocytes: assessment of targeting ability and clarification of uptake mechanism. 
 Testing the circulation behaviour in zebrafish embryos: Does PMOXA add stealth properties? 
At second, the natural polymer chitosan was used to formulate a self-assembling hydrogel. This 
involved: 
 Chemical modification of chitosan to achieve maleimide and sulfhydryl coupling, respectively: 
prove successful modification. 
 Showing gelation via Michael addition upon mixing aqueous solutions of the modified 
polymers: Microscopical evaluation of the gel’s structure, assessment of swelling and 
degradation behaviour, loading and release of protein from the gel, lyophilisation of the gel to 
improve storage capability, comparison of chitosan gel to marketed hydrogel products. 
At third, a polymer based buccal film (BF) loaded with microdoses of midazolam was tested in a 
phenotyping study. Necessary steps were: 
 Preparation of buccal midazolam control solution and buccal application of both formulations 
to volunteers. 
 Data analysis and evaluation if BF could be used for CYP3A phenotyping: AUC, Cmax, tmax, t1/2, 
CL/F of midazolam and 1’-OH-midazolam, respectively, and metabolic ratios of these. 
At fourth, a paediatric palatability study with an oral disintegrating tablet (ODT) based on 
Functionalised Calcium Carbonate was conducted. This included: 
 Study information and informed consent procedure with parents and their children. 
 Palatability assessment and evaluation of ODT acceptance by children as well as their parents: 
child-appropriate questionnaire, ODT-acceptability questionnaire for parents, facial hedonic 
scale for taste assessment, disintegration time of ODT. 
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ABBREVIATIONS 
ADME absorption, distribution, metabolism, and excretion 
ASGPR asialoglycoprotein receptor 
BF buccal film 
CNS central nervous system 
CYP450 cytochrome P450 
CYP3A cytochrome P450 3A 
EGF epidermal growth factor 
EPR effect enhanced permeability and retention effect 
FCC Functionalised Calcium Carbonate 
FHS facial hedonic scale 
GIT gastrointestinal tract 
HPC hydroxypropylcellulose 
HPMC hydroxypropylmethylcellulose 
EMA European Medicines Agency 
MCC microcrystalline cellulose 
MPS mononuclear phagocytic system 
NCL Nanotechnology Characterization Lab 
ODT oral disintegrating tablet 
PDMS poly(dimethylsiloxan) 
PEG polyethylene glycol 
PIP Paediatric Investigation Plan 
PLGA poly(lactide-co-glycolide) 
PMOXA poly(2-methyloxazoline) 
rhEGF recombinant human epidermal growth factor 
rhVEGF recombinant human vascular endothelial growth factor 
STEP Safety and Toxicity of Excipients for Paediatrics 
TPP sodium triphosphate 
VEGF vascular endothelial growth factor 
1’-OH-midazolam 1’-hydroxymidazolam 
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1 INTRODUCTION 
In this thesis, the focus is on development of different drug delivery systems – mainly based on 
polymers. At first, polymersomes, which were targeted towards hepatocytes, are described 
(chapters 1.1, 2.1, and 3.1). A self-assembling chitosan hydrogel for wound healing forms the second 
pillar of this thesis (chapters 1.2, 2.2, and 3.2). The third sub-chapter is about a polymeric buccal film 
for phenotyping that was tested in a pharmacokinetic clinical study (chapters 1.3, 2.3,and 3.3). The 
chapters 1.4, 2.4, and 3.4 refer to a study in children, assessing the palatability of an oral disintegrating 
tablet. 
 
1.1 TARGETED NANOPARTICLES FOR HEPATIC DRUG DELIVERY 
1.1.1 NANOMEDICINES FOR DRUG DELIVERY 
Many promising therapeutic compounds suffer from disadvantages such as low bioavailability, rapid 
clearance, and high systemic toxicity. To tackle these hurdles, nanoparticles as drug delivery systems 
gained increasing interest within the last decades. So called nanomedicines – including different 
classes of formulations such as drug-protein conjugates, drug-polymer conjugates, liposomes, 
micelles, and polymersomes – definitely have a great potential [1, 2]. The European Commission 
defines engineered nanomaterials as “any intentionally manufactured material, containing particles, 
in an unbound state or as an aggregate or as an agglomerate and where, for 50% or more of the 
particles in the number size distribution, one or more external dimensions is in the size range 1 nm to 
100 nm” [3]. Moreover, engineered nanomaterials are “designed for a specific purpose or 
function” [3]. Common characteristics are their small size, high surface to volume ratio, and adjustable 
physicochemical properties. In the next sections, some nanomaterials, which can be used for drug 
delivery purposes, are highlighted (Figure 1). 
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Figure 1. Schematic illustration of a selection of established nanocarriers platforms.  
 
(I) Inorganic nanoparticles include gold particles, silica and magnetic nanocarriers, quantum dots, or 
graphene nanoparticles [4]. Usually, these are easy to synthesise and modify, in addition to good 
biocompatibility and favourable physicochemical properties. Such characteristics make inorganic 
nanomaterials well suited for targeted drug delivery, cancer therapies, bio-imaging, or theragnostic 
applications – a combination of diagnosis and treatment of a disease [4, 5]. 
(II) For gene delivery, viral nanoparticles were developed. Using genetically modified, recombinant 
viral vectors, therapeutic nucleic acids such as RNA or DNA could be delivered into target cells. These 
viral nanoparticles could avoid recognition by the host immune system [6]. Common vectors are 
retroviruses, adenoviruses, adeno-associated viruses, and herpes viruses [7]. 
(III) The most popular type of nanoparticles might be lipid based nanoparticles. These were the first 
class of nanomedicines, which was developed [8]. Lipid based nanoparticles are sub-divided depending 
on their morphology: e.g. liposomes, micelles, nanostructured lipid carriers, solid lipid nanoparticles, 
or lipid polymer hybrid nanoparticles [9, 10]. On one hand, natural occurring lipids such as 
phosphatidylcholine or phosphatidylinositol can be used as building blocks for lipid based nanocarriers. 
On the other hand, artificial synthetic lipids, often synthesised from glycerophosphocholine using 
acylation and enzyme catalysed reactions, build the ground for lipid nanoformulations. Common fields 
of application are gene delivery or drug delivery with triggered drug release [11, 12]. 
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(IV) It is also possible to use polymers to prepare nanoparticles. Natural polymers such as 
polysaccharides (e.g. chitosan and cyclodextrins) or proteins (e.g. gelatine) are a well-accepted starting 
material for drug delivery systems [13–16]. High biocompatibility and biodegradability, low production 
costs, and structural flexibility are main advantages of biopolymers [16]. 
(V) In contrast to their natural counterparts, synthetic polymers are characterised by low batch-to-
batch variability. As natural polymers, synthetic ones are biocompatible and biodegradable. Moreover, 
they show a highly versatile chemistry. This makes them popular for pharmaceutical applications, for 
example as solid-sphere nanoparticles, polymeric micelles, polymersomes, polymer-drug conjugates, 
dendrimers, or polyplexes [17]. Common synthetic polymers are poly(lactic acid), poly(lactide-co-
glycolide) (PLGA), poly(ε-caprolactone), poly(dimethylsiloxan) (PDMS), poly(2-methyloxazoline) 
(PMOXA), or their copolymers [18–20]. Polymeric vesicles, called polymersomes, are formed by self-
assembly of amphiphilic block-copolymers. Comparable to liposomes, polymersomes have an aqueous 
core in which hydrophilic compounds can be encapsulated. Hydrophobic or amphiphilic molecules can 
be integrated into the hydrophobic surrounding membrane. In comparison to lipid based vesicles, 
usually polymersomes have a thicker membrane [21], resulting in improved membrane stability 
concurrent with lower permeability. Depending on the chemical composition and modification, 
biological and physicochemical characteristics of polymersomes are highly tuneable [22–24]. By 
selecting the appropriate chemical composition of each polymer-block, the desired properties of 
polymersomes (e.g. improved drug encapsulation, biocompatibility, long circulation in blood stream, 
or stimuli-responsiveness) can be achieved. This results in a broad range of block-copolymers and 
therefore a huge variety of polymersomes. In addition, it is possible to chemically modify the surface 
of polymersomes and to link targeting moieties onto it. This provides additional chemical versatility. 
Several polymeric formulations consisting of the block copolymer PDMS-b-PMOXA have been reported 
recently. Biocompatibility of the individual polymer blocks as well as low cytotoxicity in various in vitro 
models are important advantages of PDMS and PMOXA copolymers [25–28]. Moreover, PMOXA-
decorated liposomes displayed increased circulation times in blood [29] reminding of polyethylene 
glycol (PEG)-shielded nanocarriers [30]. It was suggested that PMOXA could serve as a potential PEG-
substitute to shield nanoparticles from protein adsorption by adding stealth properties to their surface. 
In accordance with these findings, polymeric nanoreactors made of tri-block PMOXA-b-PDMS-b-
PMOXA did neither induce a macrophage-mediated inflammatory response in vitro nor in vivo [31]. In 
chapter 2.1 of this thesis, polymersomes prepared of PDMS-b-PMOXA diblock copolymers are 
described. 
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Overall, main therapeutic areas for engineered nanomaterials are oncology [32], cardiovascular 
medicine [33, 34], neurology [35], anti-inflammatory drugs [34, 36], and anti-infectious treatment [37, 
38]. 
 
1.1.2 LIVER AND LIVER DISEASES 
In the field of anti-infectious treatments, one big topic are liver diseases such as hepatocellular 
carcinoma, viral hepatitis, or genetic and metabolic disorders. Liver diseases are already one of the 
leading causes of death. Unfortunately, incidence rates are still increasing [39]. The liver is the largest 
internal human organ (weighing approximately 1.5 kg in an adult). It is responsible for about 
500 different functions in the human body. Its key-functions are metabolism and clearance of endo- 
and exogenous substances. Moreover, the liver stores proteins, fats, vitamins, or iron, and produces 
proteins such as clotting factors. Other important liver functions are cholesterol homeostasis and 
immune responses (the liver is one major player of the mononuclear phagocyte system, MPS) [40–44]. 
The liver (Figure 2) is built of hexagonal formed liver lobules, being the functional units [45]. Each liver 
lobule is supplied with oxygen and nutrients by peripheral blood flow from the hepatic artery and the 
portal vein through liver capillaries (i.e. sinusoids) to the central vein [46, 47]. Non-parenchymal liver 
cells such as sinusoidal endothelial cells, hepatic macrophages (Kupffer cells), stellate cells (Ito cells), 
and parenchymal cells (i.e. hepatocytes) form the liver lobules [48, 49]. Latter account for about 
80% of the cytoplasmic liver mass. Hepatocytes are involved in many essential liver functions, for 
example metabolism of xenobiotics, protein synthesis and storage, transformation of carbohydrates, 
and bile and urea formation and secretion [50, 51]. Moreover, hepatocytes are considered as main 
pro-pathogenic cell type for many disorders including liver cancer [52], viral or parasitic liver 
infections [53], and genetic diseases with and without parenchymal damage (examples given in [54–
58]). Therefore, hepatocytes represent a very relevant target for various therapy approaches. 
The physiological function of the liver often hampers pharmacotherapies. On one hand, the liver is well 
known for its high drug uptake. On the other hand, rapid drug elimination – based on P-glycoprotein 
mediated efflux and non-specific drug uptake by Kupffer cells – hinder the treatment of liver 
diseases [59]. According to this, conventional therapeutic approaches with small molecules as well as 
novel therapeutic compounds (e.g. nucleic acids, proteins, or peptides) often show only low 
bioavailability and rapid clearance from the circulation. Therefore, increased drug doses are required 
resulting in dose-limiting side effects. Altogether, the development of alternative strategies to achieve 
efficient and specific drug delivery to hepatocytes is highly desirable [59, 60]. 
 
7 
Introduction – Targeted nanoparticles for hepatic drug delivery 
 
 
Figure 2. Schematic structure of the liver. The hepatic lobules are the functional units of the liver. Via portal vein 
and hepatic artery each lobule receives blood from the periphery. Bile is transported from the liver to the 
gastrointestinal tract through the bile duct. The hepatic arteries terminate in the hepatic sinusoids lined by 
sinusoidal endothelial cells. Kupffer cells are spread in the sinusoids’ lumen. In the perisinusoidal Space of Disse 
stellate cells are located. The parenchyma is formed by hepatocytes. Figures were adapted from [61, 62]. 
 
1.1.3 ACTIVE TARGETING OF HEPATOCYTES 
The common method to achieve nanoparticle accumulation in tumour tissue makes use of the 
enhanced permeability and retention (EPR) effect. Passage of nanoparticles through leakier vessels in 
tumour tissue and accumulation there over time is called passive targeting [63]. Additional targeting 
moieties on the surface of nanocarriers are promising, since they could further increase penetration 
of nanoparticles into solid tumours [64]. Such an approach would also help to decrease off-target 
exposure and reduce toxic side effects. Therefore, especially targeted nanomedicines allow to reduce 
the administered dose and to increase the efficiency of a therapy [65]. In the following section, four 
key characteristics, which nanomedicines should present to achieve successful hepatocyte drug 
delivery, are described [66]. 
(I) Pharmacokinetic properties of nanoparticles mainly depend on their building material, size, surface 
charge, and surface modification [67]. Nanoparticles should be smaller than 150 nm to pass the 
fenestration of liver sinusoids and to arrive at the hepatocytes. Moreover, with this size they are 
thought to be small enough not to be recognised by hepatic macrophages (i.e. Kupffer cells) [68]. The 
larger the nanoparticles the more rapidly they are cleared from circulation [69]. Also surface charge of 
nanoparticles determines their pharmacokinetic profile: Strongly positively charged nanoparticles 
easily interact with negatively charged cell surfaces, resulting in quick sequestration of these 
nanoformulations in the lung [70]. On the other hand, highly negative charge of nanoparticles triggers 
phagocytic clearance [71]. Ideally, nanoparticles that are meant to reach hepatocytes should have a 
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slightly negative surface potential (i.e. 0 to -10 mV) [72]. This could for example be achieved by 
PEGylation of nanoparticles. Formation of a bio-corona from serum proteins around such 
nanoparticles could be prevented – or at least reduced – and their unspecific uptake through 
phagocytosis is decreased [69, 73]. With such an approach the circulation half-life is increased, 
enhancing the chance of successful drug delivery to the target cell. 
(II) In order to efficiently deliver a nanoparticulate formulation to hepatocytes, active targeting plays 
a crucial role. To be considered as ideal, a target receptor should (i) be abundantly expressed on the 
cell surface to enhance the binding probability and accessibility. (ii) Moreover, a target receptor should 
be exclusively or at least predominantly expressed on the target cell type to achieve selectivity. (iii) In 
addition, target receptors should be efficiently internalised to enable uptake of the nanoparticles into 
the cell [74, 75]. Ideally, the target receptor is internalised upon receptor binding. Receptor mediated 
endocytosis results in endosome-fusion with the lysosome membrane and a pH drop down to 
pH ≤ 6.0 [76]. Upon this pH-shift, the receptors are recycled, and the internalised nanoparticles can 
escape the endosome. Liver cells are very interesting in terms of targeting as they express many 
different receptors [77]. Main receptors on hepatocytes are glycoprotein receptors 
(e.g. asialoglycoprotein receptor, ASGPR) and mannose receptors [78]. Carbohydrate receptors such 
as the ASGPR are responsible for the uptake of glycoproteins, proteins, and cellular particles – for 
example heparin and apoptotic cells [79, 80]. The ASGPR is abundantly expressed on the surface of 
hepatocytes but only minimally on extra-hepatic cells [66]. Therefore, ASGPRs are the most important 
targets to reach the hepatocytes [81]. 
Liver diseases may result in pathological tissue alterations. These might have a big influence on the 
targeting strategy by changing the accessibility or expression of the target receptor [66]. Therefore, 
the success rate of targeted nanomedicines might be improved by combining diagnostic strategies 
(e.g. to assess targeting ability) with therapeutic approaches. 
(III) The third important factor for effective development of targeted nanoparticles to hepatocytes is 
the targeting ligand. It is crucial to keep two things in mind: (i) Efficient and specific binding of the 
ligand to its receptor and (ii) optimisation of the ligand density on the nanoparticles’ surface to balance 
too low targeting ability (not enough ligand molecules) and increased opsonisation due to too high 
ligand density [82]. Possible ligands for the aforementioned ASGPR are glycoproteins (e.g. asialofetuin, 
galactose, lactose, N-acetylglucosamine, or pullulan) or some viruses (e.g. hepatitis B or C virus) [83, 
84]. 
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(IV) As a fourth factor, the availability of suitable in vitro and in vivo models must be taken into 
consideration. During development of a targeted drug delivery system to hepatocytes it is necessary 
to preclinically test the resulting formulation with suitable in vitro and in vivo models. 
 
1.1.4 ASGPR-SPECIFIC TARGETING OF PDMS-B-PMOXA POLYMERSOMES 
As outlined in section 1.1.3, the ASGPR is well suited for hepatocyte-specific drug delivery. It is a 
calcium-dependent lectin receptor that specifically binds carbohydrates with terminal galactose or 
N-acetylglucosamine residues [85]. Its physiological function is the clearance of desialylated 
glycoproteins from circulation. Binding of a ligand triggers ASGP receptor internalisation via the 
clathrin-dependent pathway [86]. It is highly advantageous that the ASGPR is species independent. The 
human as well as the rodent ASGPR recognise the same carbohydrate patterns [87]. This makes the 
ASGPR a very interesting receptor for drug development, since in vitro experiments can be directly 
compared to first preclinical in vivo experiments. 
To target the ASGPR, different asialofetuin-modified nanomaterials have already been used, such as 
polymer-lipid hybrid nanoparticles [88] and liposomes [89]. As described in section 1.1.1, polymeric 
nanocarriers are an interesting alternative to lipid based formulations [90]. Successful cellular 
targeting was recently achieved by modifying the surface of PDMS-b-PMOXA polymersomes with 
antibodies or peptides. The ligand-functionalised polymersomes were bound specifically to their target 
cells, followed by rapid cellular uptake [26, 28, 91]. This suggests that polymersomes made of 
PDMS-b-PMOXA are a promising biocompatible and versatile platform to design novel specific drug 
targeting systems. In chapter 2.1 a variety of polymersomes based on PDMS-b-PMOXA and modified 
with the targeting ligand asialofetuin are presented in detail. The focus was on formulation and surface 
modification of PDMS-b-PMOXA polymersomes for targeted drug delivery to hepatocytes. Potential 
toxicity of the resulting polymersomes was assessed in vitro using the human hepatocarcinoma 
derived HepG2 cell line. In addition, zebrafish embryos were utilised as a first vertebrate model to 
assess in vivo toxicity [92, 93].  
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1.2 CHITOSAN HYDROGEL TO TREAT CHRONIC WOUNDS 
1.2.1 HYDROGELS FOR DRUG DELIVERY 
Polymeric materials are not only used to formulate nanoparticles for systemic drug delivery as 
described in section 1.1. It is also possible to formulate mesh-like delivery systems for local drug 
delivery. Such delivery devices are made to release their cargo upon swelling and erosion as soon as 
they come in contact with water or body fluids, respectively, resulting in local drug release. It is obvious 
that such a drug delivery system has to consist of a non-toxic, biodegradable, and biocompatible 
matrix [94]. Talking about swellable systems, hydrogels are one option. Already in the 1960s, hydrogel 
research was founded by Wichterle and Lím. They synthesised hydrogels based on the 
copolymerisation of hydroxyl methacrylate and ethylene glycol dimethacrylate [95]. Hydrogels are 
crosslinked networks formed by a hydrophilic macromolecular polymer. Their polymeric backbone 
contains many hydrophilic moieties (e.g. hydroxyl, carboxylic, sulphate, or amine groups) and allows 
hydrogels to imbibe large amounts of water [96]. Their physical properties such as swelling, 
permeation, mechanical strength, and surface characteristics can be changed by structural 
modification [97]. Especially the fields of drug delivery, biosensing, and tissue engineering profit from 
hydrogel based drug delivery systems [98, 99]. Hydrogels are classified as physical or chemical 
hydrogels depending on the type of bonds that are formed during their fabrication process. 
Physical hydrogels, also called reversible hydrogels, are formed by noncovalent binding strategies such 
as electrostatic interactions, hydrogen bonding, or hydrophobic forces. The main advantage of physical 
hydrogels is based on their non-covalent formation: no potentially toxic covalent linker molecules are 
required. But this is again also a drawback, since reversible hydrogels may lack mechanical strength 
and dissolve in an uncontrolled manner [98, 100]. 
In contrast, chemical hydrogels are stabilised and held together by covalent bonds wherefore they are 
termed permanent hydrogels. They are formed by irradiation chemistry, secondary polymerisation, or 
by using small crosslinker molecules resulting in irreversibly crosslinked polymer chains. Therefore, 
they show a stable network structure allowing absorption of water and diffusion-mediated drug 
release. However, the methods applied to form such permanent hydrogels might be less biocompatible 
than the ones leading to physically crosslinked hydrogels [100]. 
By using pre-functionalised polymer chains with reactive functional groups, a covalently crosslinked 
hydrogel can be prepared without need for any additional crosslinker molecule [101, 102]. For 
example, disulfide-bond formation between the single polymer chains [103], Schiff bases 
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reactions [104], or Michael addition [105, 106] result in such stable hydrogels. These combine the 
advantages of physically and chemically crosslinked gels.  
Up to now, polymeric hydrogels were used for a broad variety of applications. In this section a few are 
shortly described: To fight the increasing antibiotic resistance in pathogenic microbes, locally applied 
antibiotics may offer an opportunity. For such local antibiotic drug delivery, hydrogels are a very 
interesting solution due to their high hydrophilicity, unique three-dimensional network structures, 
biocompatibility, cell adhesive properties, and even inherent antimicrobial activity [107]. The 
combination of antibacterial agents with nanomaterials such as hydrogels could help to lower the 
doses compared to systemically administered antibiotics. This is expected to alleviate the problems of 
resistance and undesired side effects to some extent. It is also possible to use polymeric hydrogels for 
ocular drug delivery. Such formulations are characterised by a prolonged drug release [108]. 
Additionally to ocular drug delivery, also nasal drug delivery is a field of hydrogel research [109]. The 
mucoadhesive properties of hydrogels result in prolonged residence time on the nasal mucosa 
increasing the contact time and therefore mucosal drug absorption. But not only topical application of 
hydrogels is an option. Also injectable hydrogels can be designed to deliver bio-therapeutic 
molecules [96, 110, 111]. These could serve as drug or gene delivery system or form a cell-growing 
depot in the body upon a single injection of an in situ forming hydrogel. For example, local 
intratumoural delivery of chemotherapeutics by injection of hydrogel drug depots is a very promising 
idea [112]. Other fascinating fields for hydrogel application are tissue engineering and regenerative 
medicine [113]. Mimicking key characteristics of natural tissue, i.e. retention of large amounts of 
water, effective mass transfer, and ability to form different shapes, makes hydrogels very interesting 
for these applications. Amongst others, one special focus is on hydrogels as bioactive materials to 
encapsulate stem cells [114]. Hydrogels could successfully mimic the three-dimensional shape of 
extracellular matrix, providing a friendly growth environment for stem cells. 
 
1.2.2 CHITOSAN: ONE POSSIBLE NATURAL POLYMER TO FORMULATE HYDROGELS 
Several different polymers can be chosen to create hydrogels. Comparable to the preparation of 
polymeric nanoparticles (chapter 1.1.1), synthetic and natural polymers are used, offering different 
advantages and disadvantages. Natural polymers originate from plants, algae, animals, or different 
microbial populations, which makes them comparatively inexpensive [96]. Advantages of natural 
polymers are biocompatibility, lack of toxicity, and good interaction with the surrounding tissue [96]. 
Synthetic polymers offer even broader opportunities to modify their mechanical and degradation 
properties. Therefore, hybrid systems out of natural and synthetic polymers have already been 
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designed [96]. Well known examples for synthetic polymers are poly(acrylamide), acrylic acid, PEG, 
pyrrolidone, or derivatives of them [107]. Polymers from natural sources include polysaccharides 
(e.g. hyaluronic acid, cyclodextrin, alginate, carboxymethyl cellulose, and chitosan) and protein based 
polymers (e.g. gelatine, fibrin, and collagen) [96]. In the following section, the natural polymer chitosan 
(Figure 3 B) is described in more detail. It is the most important derivative of chitin (Figure 3 A), which 
itself can be found in the exoskeleton of insects and marine invertebrates, in some microorganisms, 
and in the cell walls of fungi [115]. 
 
Figure 3. Chemical structure of A) chitin and B) chitosan. 
 
Chitosan is partially de-N-acetylated chitin and consists of glucosamine and N-acetylglucosamine 
copolymers. Removing acetyl moieties from chitin (either by amide hydrolysis under alkaline 
conditions or by enzymatic hydrolysis) leads to chitosan [116]. It is preferred over its parent substance 
for biomedical applications due to its better solubility in water and organic solvents [117]. Chitosan 
combines biocompatible, biodegradable, bio-renewable, and non-toxic properties. Moreover, it is 
highly mucoadhesive and able to transiently open tight junctions [118]. Chitosan shows tissue 
regenerative effects [119], is fungi-static [120], haemostatic [121], hypocholesterolemic [122], 
tumour-suppressive [123], as well as immune-stimulating [124]. In addition to these many great 
properties, chitosan offers a huge potential for chemical and mechanical modifications to create new 
properties and functions. These make it a very promising scaffold for hydrogels. 
De-N-acetylation of chitin results in free amino moieties in the chitosan backbone. Therefore, chitosan 
becomes soluble under acidic conditions due to protonation of the amino residues. Additionally, the 
viscosity and molecular weight of chitosan can be controlled by pH changes [115]. The relative 
proportion of glucosamine to N-acetylglucosamine determines many properties of the hetero-polymer 
such as solubility and acid-base behaviour [125]. In addition to the amino group, chitosan possesses 
two hydroxyl moieties on each glucoside residue. These can be easily modified in order to adjust 
biological, chemical, and physical properties [115]. As mentioned above, one main advantage of 
chitosan is its biodegradability. In a physiological environment harmless degradation products are 
formed by chitinase, chitosanase, or lysozyme [126]. These break the glycosidic bonds of the 
polysaccharide backbone, resulting in oligosaccharides of different length [127]. 
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Chitosan is not only used in biomedicine [102, 127] but also in food industry [128–130], 
cosmetics [131, 132], or for water treatment [133, 134]. 
 
1.2.3 MODIFICATIONS OF CHITOSAN 
In order to even broaden the spectrum of potential applications – especially for pharmaceutical 
purposes – the modification of polymers has gained huge attention [115]. The basis for many chitosan 
modifications is laid by the amino and hydroxyl moieties [135]. These can be used for several 
interactions with other polymers or biological molecules. The most common techniques to modify 
polymers, are blending and chemical functionalisation, including graft co-polymerisation [115]. 
Physical modification is achieved by blending. It results in physical mixtures (homogenous or more-
phase structures) of at least two polymers. Compared to the former single polymers, blended polymers 
offer new physical properties [136] such as improved mechanical, chemical, structural, biological, or 
morphological characteristics. Advantages of blending are the short time required [137] and the huge 
variety of properties that can be tailored to certain applications [115]. Chitosan was for example 
blended with other hydrophilic polymers, i.e. poly(vinyl alcohol), poly(ethyl oxide), or poly(vinyl 
pyrrolidone) [138]. Among others, these blends were investigated as oral drug delivery systems [138], 
as well as to improve mechanical properties of medical products, and to achieve controlled drug 
delivery [115]. 
Functionalisation means chemical modification of the polymeric surface to improve certain properties 
such as adhesion or biocompatibility and to modify physico-chemical properties (e.g. electrostatic 
charging or permeation of polymeric surfaces). For example, carboxylic acid and hydroxyl moieties 
increase on one hand hydrogen bonding and on the other hand they enable further chemical covalent 
modifications [139]. Chitosan was modified by several methods, for example thiolation (as described 
in chapter 2.2), co-polymerisation, or alkylation [140, 141]. 
The method of graft co-polymerisation describes a process of covalently binding one polymer to the 
other. This might happen within seconds or even last for several hours [142, 143]. 
 
1.2.4 WOUND HEALING AND WOUND DRESSINGS 
Wound dressings are used to facilitate wound healing. Among other characteristics, they should 
protect the wound from contamination, keep a moist wound environment in order to support wound 
closure, and ensure sustained and effective delivery of applied bioactive substances [144, 145]. Of 
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course, the perfect wound dressing would be skin. Therefore, researchers try to mimic this gold 
standard as close as possible. At the beginning of wound dressing research, wound dressings were 
mainly protective and had a passive role in the healing process. This approach has changed during the 
last decades towards specialised biocompatible materials supporting the natural process of wound 
healing [146]. By providing a moist wound environment, proliferation and migration of fibroblasts and 
keratinocytes is induced. Moreover, scar formation is reduced by enhanced collagen synthesis. These 
new materials are also recognised as very acceptable and beneficial by patients as they can be easily 
removed without causing pain and trauma during dressing change. In addition, they reduce wound 
exudates, or odour from a wound [147]. 
Such specialised wound dressings are particularly important for patients with chronic wounds. In 
diabetic ulcers, venous stasis ulcers, or decubitus ulcers, cutaneous wound healing is a major problem. 
The process of cutaneous wound healing is a very complex interaction between several factors, which 
– in most cases – results in timely restoration of an intact skin barrier. But this multistep process of 
wound healing is easily prone to interruption. Several pathologic factors might favour the formation 
of chronic wounds. Examples are peripheral vascular disease, which influences the wound’s blood 
supply, immunosuppression or acquired immunodeficiency, metabolic diseases such as diabetes, 
certain medications (e.g. anticoagulants or corticoids), radiation therapy resulting in previous local 
tissue injury, or external factors like temperature, sustained pressure, and moisture. Chronic wounds 
are the result – difficult and expensive to treat. In the United States alone, the number of patients with 
chronic wounds is estimated to exceed 6.5 million; treating these patients requires more than 
US$ 25 billion per year [145]. 
Physiological wound healing (Figure 4) is characterised by three main phases: inflammation, fibroblast 
proliferation, and epithelialisation [148]. Uncomplicated wound healing results in a fine scar with little 
fibrosis, sometimes some wound contraction, and almost normal tissue architecture and organ 
function [148]. A chronic wound describes a healing process that does not happen in orderly or timely 
sequence, or where the result lacks structural integrity [149]. Abundant granulation tissue forms and 
often disproportionate fibrosis results in distinct scar contraction and loss of tissue function [148]. 
(I) Within the first 5 to 10 minutes after an injury, haemostasis begins and is supported by an intense 
vasoconstriction. To achieve successful tissue healing and regeneration, the wound is cleared from 
foreign material and dead tissue. Within 20 minutes after the trauma, the inflammatory phase starts. 
It is characterised by local vasodilation and increased capillary permeability. Haemostasis is supported 
by platelet adhesion and clot formation at the site of injury [148]. These platelets are the depot for 
many vasoactive substances and growth factors (i.e. epidermal growth factor, β-thromboglobulin, 
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platelet-derived growth factor, platelet factor 4, transforming growth factor β, angiogenesis factor, 
fibroblast growth factor, bradykinin, serotonin, prostacyclins, prostaglandins, histamine, and 
thromboxane) [150]. In addition, the complement cascade is initiated, and leukocytes are guided by 
chemotaxis to infiltrate the wound bed. Their interplay with lysosomal enzymes, free oxygen radicals, 
collagenases, elastases, and neutral proteases protects the wound from infections and keeps it clear 
from tissue debris. The increased capillary permeability allows neutrophils and monocytes to enter the 
interstitial space. Macrophages and lymphocytes start to replace the leukocytes. They guide fibroblasts 
to the wound, where these can adhere on a scaffold of mainly fibronectin and hyaluronate, produced 
24-48 hours after injury [148, 151]. In addition to phagocytosis and cell migration, macrophages are 
also key drivers for tissue proliferation and subsequent collagen synthesis and degradation [148, 152]. 
(II) Within 2 to 3 days, the fibroblast proliferation phase starts and lasts for about one week. 
Fibroblasts produce essential substances for wound repair, i.e. collagen and glycosaminoglycans such 
as hyaluronic acid, chondroitin-4-sulfate, heparin sulfate, and dermatan sulfate. These are mainly 
involved in deposition and aggregation of collagen fibres, which are constantly produced during this 
time until about three weeks after injury. Rapid growth of endothelial cells and angiogenesis within 
the granulation tissue create a very active healing environment within the wound. The increasing 
content of collagen results in increasing wound tensile strength. Wound maturation is characterised 
by a homeostasis between collagen synthesis and degradation. Remodelling begins with collagen fibres 
reorganising into a more structured lattice. The extracellular matrix starts to be reorganised. The 
tensile strength of the wound further increases, but in best cases only 80% of the maximum tensile 
strength of healthy skin can be reached [145, 148]. 
(III) The epithelialisation phase represents another milestone of wound healing. Epithelial cells 
migrate and grow from the bottom of the wound to their edges, covering the complete wound. 
Epithelialisation involves mobilisation, migration, mitosis, and cellular differentiation of these cells. 
Already during the earlier phases, wound contraction is induced by specialised fibroblasts to minimise 
the wound size and close potential defects. However, if this process is not controlled properly, it can 
lead to disorganised structural integrity, loss of function, and hypertrophic scar formation [148]. 
During the different phases of physiological wound healing, granulation tissue – rich in capillaries, 
fibroblasts, inflammatory cells, and endothelial cells – is converting to a collagen matrix. Apoptosis is 
the key driver to create this relatively avascular and acellular structure. If this process of controlled 
apoptosis fails to occur in a timely manner, chronic wounds with high cellular activity and eventually 
abundant scar tissue will be the result [148]. 
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Figure 4. Phases of physiological wound healing. ECM – extracellular matrix. Figures were adapted from [153, 
154]. 
 
The morbidity associated with chronic wounds has resulted in an increasing importance of good wound 
care. Moist occlusive dressings are used to support the inflammatory phase and re-
epithelialisation [155]. Moreover, autolytic wound debridement – necessary for successful wound 
healing – is enabled in such a moist environment. In contrast, traditional dry gauze dressings inhibit 
this process and bear the risk for further injury when being removed from the wound. Therefore, 
classical wound dressings nowadays are low adherent dressings, which maintain a moist wound 
environment while allowing exudate to pass through a secondary dressing. Low adherent dressings are 
manufactured in such a way that they reduce adherence at the wound bed to make dressing changes 
as less painful as possible [155]. Another typical class of wound dressings are semipermeable films. 
These allow air and water vapour exchange whilst being impermeable to fluids and bacteria [155]. 
Hydrocolloids consist of a semipermeable film or foam as backing material crosslinked to a hydrophilic 
layer of for example gelatine, collagen, cellulose, or pectin. They form an occlusive, adhesive wound 
dressing that jellifies on the wound surface to promote a moist wound environment [144, 155]. In 
contrast, hydrogels are permeable to moisture vapour and oxygen. Depending on the secondary 
dressing, bacteria and fluids can permeate. As mentioned in section 1.2.1, hydrogels consist of a 
polymeric matrix containing large amounts of water and are able to donate this water to the wound 
bed resulting in a moist wound environment. The process of swelling and shrinkage is reversible, which 
allows hydrogels to adapt perfectly to the actual situation in the wound [146, 155]. For moderately 
18 
Introduction – Chitosan hydrogel to treat chronic wounds 
 
exudative wounds foams can be chosen. They are made from silicone or polyurethane foam and are 
permeable to oxygen and moisture vapour [145]. Another option are alginate dressings, which are 
used for highly exudative wounds. Upon contact with wound exudate they partly dissolve and form a 
hydrophilic gel [155]. It is also possible to use collagen products that help to attract cell populations 
necessary for wound healing and to reduce negative factors such as proteases and free radicals [145]. 
In addition, dressings can be antimicrobial, e.g. silver- or iodine-impregnated dressings, to treat burns 
and infected wounds [155]. It is also possible to produce bioactive wound dressings. These dressings 
contain agents beneficial for wound healing such as steroids, antibiotics, or growth factors [146]. The 
latter promote wound healing by supporting cell migration, proliferation and differentiation in the 
wound bed [156]. 
In chapter 2.2, a chitosan based hydrogel is described, which was prepared out of two chemically 
modified chitosan polymers. The gel formed as soon as the two polymers were mixed – without need 
for additional crosslinking agents. The hydrogel could be lyophilised and rehydrated successfully. In 
addition, loading and afterwards release of a model protein from this hydrogel was achieved. These 
properties make it a promising scaffold for biological wound dressings in the field of chronic wound 
treatment. 
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1.3 BUCCAL FILMS FOR PHENOTYPING: A PHARMACOKINETIC STUDY 
1.3.1 CYP3A METABOLISM 
Cytochrome P450 (CYP450) enzymes are a superfamily of 57 human enzymes. Their main functions are 
oxidative, reductive, and peroxidative metabolism of various exogenous and endogenous compounds 
(phase I metabolism). About 80% of the drugs on the market nowadays are metabolised via 
CYP450 [157]. Moreover, CYP450 enzymes are involved in cholesterol metabolism, bile-acid 
biosynthesis, steroid synthesis and metabolism, vitamin D3 synthesis and metabolism, and retinoic acid 
hydroxylation. CYP450 enzymes are located in epithelial cells of the small intestine and in the smooth 
endoplasmic reticulum of hepatocytes [158]. 
Not all 57 human CYP450 variants are involved in drug metabolism. The five major drug metabolising 
CYP450 are CYP3A4, CYP2D6, CYP1A2, CYP2C9, and CYP2C19. These are responsible for about 60% of 
drug metabolism [159]. Not only in terms of activity but also when it comes to expression levels, the 
CYP3A family is the most abundant in human liver and intestine, accounting for about 50% of the 
CYP450 enzymes [160, 161]. CYP3A4 and CYP3A5 are the two most active enzymes of the CYP3A family. 
Both show very similar substrate specificity, which cannot be distinguished easily. Other members of 
this family show either only very low activity, such as CYP3A43, or are for example only expressed in 
foetuses, such as CYP3A7 [161]. CYP3A enzymes metabolise a very broad range of chemically unrelated 
drugs from almost every drug class. It is assumed that CYP3A is involved in the metabolism of more 
than 50% of the therapeutic agents undergoing oxidative alterations [161, 162]. Therefore, it is not 
surprising that such essential metabolism pathway can be easily affected by various drug-drug 
interactions. These include either inhibition of CYP3A enzymes or increase of CYP3A expression and 
therefore higher metabolic activity. As a result, enzyme activity may vary up to 400-fold [163]. Thus, 
plasma concentrations of co-administered drugs can change tremendously resulting in either reduced 
activity or toxic side effects. Some serious and well-known examples for such drug-drug interactions 
are presented below. 
Co-administration of CYP3A inhibitors (e.g. diltiazem, verapamil, or nitroimidazole antifungal agents) 
with erythromycin (extensively metabolised by CYP3A) results in over-dosing with erythromycin and 
therefore prolonged cardiac repolarisation. Torsades de pointes may occur leading to sudden 
death [164]. Erythromycin itself is, due to its extensive metabolism by CYP3A, competitively inhibiting 
this enzyme subfamily. In combination with simvastatin this may result in myopathy or 
rhabdomyolysis, signs of intoxication with this lipid-lowering drug [165]. Another very important 
CYP3A inhibitor is grapefruit juice that is known to interact with more than 85 drugs. In combination 
with for example immunosuppressants like sirolimus or cyclosporine this may result in nephrotoxicity 
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and myelotoxicity [166]. Usually, CYP3A inhibition is reversible within two to three days once the 
inhibiting drug is stopped. However, some CYP3A inhibitors destroy the enzyme and new CYP3A must 
be synthesised. This is the case for example with diltiazem and macrolide antibiotics [161]. 
CYP3A inducers (e.g. rifampicin, phenobarbital, phenytoin, many glucocorticoids) up-regulate CYP3A 
expression. Therefore, previously active doses of CYP3A substrates may become ineffective, or toxic 
metabolites of these substrates can lead to intoxication. For example, oral contraceptives containing 
the CYP3A substrate etinylestradiol combined with CYP3A inducing agents may result in breakthrough 
vaginal bleeding or even pregnancy [161]. Moreover, patients taking the immunosuppressant 
cyclosporine or HIV-protease inhibitors co-administered with the potent CYP3A inducer St. John’s wort 
may suffer from therapy failure [167, 168]. In contrast to CYP3A inhibition, the effects of CYP3A 
induction are not immediate as they are based on new CYP3A synthesis. Usually, it takes two to three 
weeks until steady-state levels are reached and several weeks until the induction effect is “washed-
out”, once the inducer is discontinued. 
 
1.3.2 MIDAZOLAM FOR CYP3A PHENOTYPING 
From the examples given above it becomes clear that especially drugs with a narrow therapeutic 
window need to be dosed very carefully based on the patient’s individual metabolising activity. For 
clinical practice, this means that an easy and reliable phenotyping tool is needed to tailor dose 
recommendations in patient treatment. By administration of a test drug followed by measurement of 
the metabolic ratio (in blood plasma, urine, saliva, or tissue) the metabolic activity of a patient 
regarding the tested enzyme can be determined. Phenotyping provides information about the activity 
of a certain drug metabolising enzyme at a given time point. It reflects genetic factors as well as 
non-genetic and environmental factors (Figure 5). The main prerequisite for phenotyping is that the 
metabolism of the test drug is exclusively dependent on the tested enzyme [169, 170]. 
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Figure 5. Difference between geno- and phenotype. The genotype of a person is exclusively determined by 
genetic factors whereas the phenotype also reflects several environmental influences on a person. 
 
To phenotype CYP3A, midazolam is a well-accepted probe drug [163, 171–175]. This short-acting 
benzodiazepine is sedative, anxiolytic, anticonvulsive, and muscle-relaxant. For insomnia treatment 
typical doses are between 7.5-15 mg per os. Within 20 minutes, the sedative effect starts and after 
7-8 hours of sleep the effect is usually resolved. After oral administration, midazolam has an absolute 
bioavailability of 30-50%, and the peak concentration is reached within one hour. The elimination half-
life time is between 1.5-2.5 hours. Almost 100% of the midazolam dose are eliminated after 
biotransformation. The hepatic oxidative metabolism involves CYP3A4 and CYP3A5. These hydroxylate 
midazolam to 1’-hydroxymidazolam (1’-OH-midazolam) and 4’-hydroxymidazolam. This step is 
followed by either further hydroxylation to 1’,4’-dihydroxymidazolam and/or glucuronidation and 
elimination via urine (Figure 6). The main metabolite in plasma and urine is 1’-OH-midazolam and 
60-80% of the initial dose can be found in the urine as glucuronidated 1’-OH-midazolam. 
1’-OH-midazolam is pharmacologically active (about 34% of the effect of orally administered 
midazolam) and plasma concentrations of this metabolite reach about 30-50% of the parent 
substance [176, 177]. 
Intravenously administered midazolam is used as sedative, as pre-medication before anaesthetic 
induction, or directly for anaesthesia. The total doses range between 1-7.5 mg. Already after 
2 minutes, first effects appear and within 5-10 minutes the peak concentration is reached. 
Intravenously administered midazolam is metabolised extensively by CYP3A as well. The main 
metabolite is – comparable to oral administration – 1’-OH-midazolam. Its plasma concentration 
reaches about 12% of midazolam. The pharmacological effect of 1’-OH-midazolam after intravenous 
administration is not as significant as after oral administration (about 10%). The metabolism and 
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elimination pathway is of course the same as for oral midazolam, with a half-life time of 1.5-2 hours, 
and comparable hydroxylation and glucuronidation patterns [176]. 
 
Figure 6. Metabolism of midazolam. CYP3A4 and CYP3A5 transform midazolam to 1’-hydroxymidazolam, 
4’-hydroxymidazolam, and 1’,4’-dihydroxymidazolam. All metabolites and the parent substance undergo rapid 
glucuronidation via uridine diphosphate-glucuronosyl-transferases (UGTs) followed by elimination via urine. 
UGTs are divided into two subfamilies, UGT1 and UGT2 [178–181]. 
 
From the information above, it becomes clear that midazolam is very well suited to serve as 
phenotyping test drug to determine the activity of CYP3A. For this purpose, plasma concentrations of 
midazolam as well as its main metabolite 1’-OH-midazolam are measured. By using metabolic ratios of 
parent to metabolite plasma concentrations, the CYP3A activity of every single patient can be 
determined and dose recommendations for CYP3A drugs could be made. In order to avoid sedation of 
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every tested patient due to pharmacologically active midazolam doses, a microdosing approach for 
phenotyping was recently developed [174]. Halama and co-workers found that oral midazolam kinetics 
are linear over a 30’000-fold range and already doses as small as 300 ng can be used to predict drug 
interactions with strong CYP3A inhibitors [174]. However, the development of drug formulations 
containing microdoses as well as their administration remain a challenge. One opportunity to tackle 
this is to use microdosed oral films. 
 
1.3.3 ORAL FILMS 
In general, oral films are divided into oral disintegrating films and buccal films (BFs). Oral disintegrating 
films can be either mucoadhesive or non-mucoadhesive and they disintegrate rapidly in the oral cavity. 
After swallowing them they are absorbed in the gastrointestinal tract (GIT). Depending on the amount 
and type of drug that they are containing an oral absorption is also possible. BFs are always 
mucoadhesive and the oral absorption of drug results in a fast onset of action. BFs can be placed either 
sublingual, buccal, or palatal. Regarding oral absorption, the residence time of the drug within the oral 
cavity plays an important role. Additionally, one should consider the oral mucosa saturation. Beside 
the fast onset of action, main advantages of oral absorption are that the drugs are not destroyed by 
harsh conditions in the GIT nor are they exposed to first pass metabolism. Therefore, it is possible to 
lower the required dose strength what again improves the safety and efficacy profile of a drug [182]. 
Oral films possess several advantages. Due to their appellative form and their inherent ease of 
administration they are very well accepted by patients. This is particularly important for special patient 
populations such as paediatric or geriatric patients who might have difficulties with swallowing [183]. 
Moreover, oral films can hardly be spit out. That makes them also well suited for bedridden or 
non-cooperative patients. In addition to high compliance, oral films are beneficial for drugs with a 
narrow therapeutic window and for those requiring a precise dose adaption in phases of initial drug 
monitoring. Not only with regards to patients, but also in direct comparison to other oral formulations, 
oral films offer many advantages. In contrast to several oral disintegrating tablets, oral films are more 
stable, resistant, flexible, and better portable. Moreover, the dosing accuracy and ease of 
administration of oral films is preferable compared to liquid oral formulations requiring a careful 
volume measurement and often cautious shaking before administration. In terms of transportation, it 
is also better to work with oral films, since they require much less space and weight. Moreover, liquid 
oral solutions tend to have stability issues. Major drawbacks of oral films are their instability in very 
humid regions and their limited ability to load higher amounts of active pharmaceutical ingredients. 
The latter challenge was already tackled by some companies and Gas-X Strips® are an example that a 
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drug load of more than 50% is possible. Due to the fact that oral films are in direct and comparably 
long contact to the oral mucosa, taste masking is an important question to be discussed [182]. 
Additionally, oral films are not suited for active pharmaceutical ingredients that are unstable at 
mucosal pH or that are irritating the oral mucosa [183]. 
Comparable to the formulations described in sections 1.1 and 1.2, polymers are also the key 
component of oral films. One or more polymers control the properties of the resulting films: their 
mucoadhesiveness, disintegration time, mechanical strength, elasticity, handling properties, and drug 
loading capacity [182]. In the following paragraph, the polymers that were used to formulate the 
midazolam BF (chapter 2.3) are highlighted. 
Cellulose derivatives are often used for oral films. To formulate the midazolam-containing BF, 
hypromellose, hydroxypropyl cellulose and microcrystalline cellulose were processed. Hypromellose, 
short for hydroxypropylmethylcellulose (HPMC), is one of the most used excipients. HPMC is partly 
O-methylated (-OCH3) and O-(2-hydroxypropylated) (-OCH2-CH(OH)-CH3) cellulose (Figure 7 A). As 
chitosan (section 1.2.2), HPMC exists in several grades with different molecular weights 
(i.e. 10-150 kDa) and varying degree of substitution resulting in tuneable oral film properties [184]. It 
was shown that the HPMC grade influences the dissolution profile and drug substance release. The 
higher the hydroxypropyl/methoxyl ratio the slower was the release [185]. Moreover, polymers with 
a higher viscosity due to increased branching and/or longer polymer chains tend to produce more 
resistant, stiff, and extensible polymeric matrices [182]. It is well known that a combination of HPMC 
with microcrystalline cellulose and plasticisers such as PEG 400 (as it is presented in chapter 2.3) results 
in good film forming properties [186]. Another cellulose derivative is hydroxypropylcellulose (HPC). 
Herein, the hydroxyl residues of cellulose are hydroxypropylated (-OCH2-CH(OH)-CH3) (Figure 7 B). As 
HPMC, HPC exists in several substitution grades with different molecular weights between 
60-1200 kDa [184]. Using HPC for film formation results in mechanically stable films with good carrying 
capacity and moderate bioadhesive properties [182, 187]. HPC is soluble in many different 
solvents [184]. This enables researchers to flexibly select the solvent according to the solubility of the 
drug that should be loaded into the oral film. Microcrystalline cellulose (MCC) (Figure 7 C) is partly 
depolymerised α-cellulose with a resulting polymerisation degree around 120-300. In comparison to 
unmodified cellulose powder, MCC is easier to be compressed, shows improved flowability, and is 
mechanically more stable. Moreover, MCC is very useful as disintegrant due to wicking effects as soon 
as it comes in contact with liquid [184]. 
Another common polymer used for film formation is starch. It is a promising biopolymer because of its 
wide availability, biodegradability, and low costs [188]. Starch is a combination of amylopectin 
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(Figure 7 D) and amylose (Figure 7 E), typically in a ratio of 75-85% amylopectin and 
15-25% amylose [184]. To prepare strength, water resistant, thermally stable, and easily processable 
films, starch is usually blended with other polymers [188]. For the midazolam BF, described in this 
work, hydrolysed starch in the form of maltose (Figure 7 F) was used [182]. Films containing such 
Maltodextrins are characterised by fast disintegration and dissolution times [189]. 
The synthetic macromolecule PEG 400 is a polycondensation product of ethylenoxide (Figure 7 G). 
PEGs exist in various polymerisation grades with molecular weights ranging mainly from 200 to 
7000 g/mol. PEG 200 to PEG 600 are liquid at room temperature, whereas PEGs with a higher 
molecular weight are semisolid or solid at this temperature. PEGs can be used for many different 
purposes, such as solvent, solubility enhancer, lubricant, embedding material, basis for ointments or 
suppositories, or as plasticiser [184]. In the midazolam BF PEG 400 is used as plasticiser. 
 
Figure 7. Chemical structures of common polymers used in oral films. A) hydroxypropylmethylcellulose (HPMC), 
B) hydroxypropylcellulose (HPC), C) microcrystalline cellulose (MCC), D) amylopectin, E) amylose, F) maltose, and 
G) polyethylenglycol (PEG) 400. 
 
In chapter 2.3, the use of a BF containing microdoses of midazolam is described. It was applied onto 
the palatal mucosa of healthy volunteers and the plasma concentrations of midazolam and 
1’-OH-midazolam were determined for 12 hours. It was shown that the BF described in this study 
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facilitated oral absorption of midazolam, resulting in plasma concentrations that would be comparable 
to intravenously administered midazolam. Moreover, the plasma concentration-time profiles of this 
microdosed BF and a buccal solution containing the same amount of midazolam were comparable if 
the solution was administered into the buccal cavity, resulting in oral absorption as well. With respect 
to the presented results it would be also possible to perform a limited sampling strategy using the BF, 
as it was already proposed for other CYP3A phenotyping methods [190]. To use microdosed midazolam 
BFs for phenotyping would be very attractive especially for vulnerable patient populations where 
adverse drug reactions and drug-drug interactions are highly expected and where drug administration 
may create some difficulties. Amongst others, this is the case for paediatric patients [191, 192] as well 
as geriatric patients with multimorbidity [193]. 
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1.4 ORAL DISINTEGRATING TABLETS: A PALATABILITY STUDY IN CHILDREN 
1.4.1 PAEDIATRIC PATIENTS 
The paediatric population is very heterogeneous. Physical, cognitive, and psychosocial abilities develop 
gradually but also individually with flowing transitions between the different age categories. 
Therefore, it is necessary to consider each paediatric patient as individual depending on the 
development. In the following sections, the paediatric age groups are described [194, 195]. 
(I) Preterm newborn infants (born before 37 weeks of pregnancy [196]) include 25-week gestation 
newborns, weighing 500 g, as well as 30-week gestation babies with 1500 g, or low-birth-weight 
newborns. It is obvious that this group presents special challenges regarding studies of medicinal 
products due to the unique pathophysiology and responses to therapies of preterm newborn infants. 
It should be always evaluated whether these children are immature or growth-retarded. For this 
purpose, several factors might be considered: (i) Their gestational age at birth and age after birth has 
to be kept in mind [194]. The corrected age refers to the age calculated from the expected date of 
delivery [195]. (ii) The activity of hepatic and renal clearance mechanisms is not fully developed [195, 
197]. (iii) Fast and highly variable development of physiological and pharmacological processes results 
in rapidly changing dose recommendations. (iv) Protein binding differs from older children. Moreover, 
displacement issues, e.g. bilirubin, need to be kept in mind. (v) Preterm newborns possess only an 
immature blood-brain barrier, which is not able to protect the central nervous system (CNS) from 
potentially toxic substances. (vi) The skin barrier is not as efficient as in older paediatric patients. Due 
to increased transdermal absorption potential intoxication with medicinal products or other chemicals 
might occur. (vii) Distinct cardiac (e.g. patent ductus arteriosus) and pulmonary (e.g. respiratory 
distress syndrome) conditions are specific for neonates and must be monitored carefully. Moreover, 
preterm newborn infants show unique susceptibilities such as intraventricular haemorrhage [194, 
195]. 
(II) Term newborn infants (aged 0 to 27 days) are comparable to preterm newborn infants regarding 
the physiological and pharmacological principles discussed above, with the difference that term 
newborns are developmentally more mature. Compared to older children, term newborn babies differ 
significantly: (i) The blood-brain barrier is still not fully developed allowing the entrance of potentially 
toxic substances into the CNS. (ii) Their body water and fat content vary from older children and their 
body-surface-area-to-weight ratio is much higher resulting in different volumes of distribution of 
medicinal products compared to older paediatric patients. (iii) It is more difficult to predict the oral 
bioavailability in newborns than in older children. The gastrointestinal absorption is influenced by 
several factors such as surface area, gastric and intestinal pH, intestinal mobility and transit time, tissue 
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perfusion, and maturation of transporters and receptors. All of them develop and mature over time. 
(iv) Highly variable and rapidly changing metabolism pathways require dose adjustments on at least 
weekly (if not daily) basis. For this purpose, not only pharmacokinetic changes but also 
pharmacodynamic changes should be considered [194, 195]. 
(III) Infants and toddlers (aged 28 days to 23 months) are characterised by (i) rapid CNS development 
and (ii) maturation of their immune system. (iii) They grow quickly and changes in body composition 
such as age-related changes in fat, muscle, and total body water composition might have significant 
impact on volume of distribution, peak plasma concentrations, and half-lives. (iv) The oral absorption 
becomes more predictable and (v) metabolic pathways such as hepatic and renal clearance continue 
to mature rapidly [194, 195]. Aged 1 to 2 years, the children’s clearance of many compounds (based 
on mg/kg) can exceed the adults’ one [197]. It has to be kept in mind that the maturation of clearance 
pathways is strongly influenced by inter-individual fluctuations [194]. 
(IV) Children (aged 2 to 11 years) possess (i) mostly mature clearance pathways with often more active 
clearance capacities than adults. (ii) During this long period of time, psychomotor development is very 
important and might be easily affected by CNS-active drugs. (iii) The effects and acceptance of 
medicinal products can be determined more easily than in younger children due to increased cognitive 
and motor skills. Moreover, skeletal growth, weight gain, school attendance, and school performance 
can be measured to gather information about ongoing therapies. (iv) Towards the end of this age 
period, puberty starts to begin [194]. Typically, onset of puberty in girls is from 8 to 9 years of age, 
which is a little bit earlier than in boys (around 10 years or older) [198]. With this period, clearance 
capacity may change significantly, what makes dose adjustments necessary [194]. Due to the very 
broad range of developmental differences within this population of 2 to 11 year-old children, the 
European Committee for Medicinal Products for Human Use divided it into two subgroups: preschool 
children (aged 2 to 5 years) and school-going children (6 to 11 years old) [199, 200]. 
(V) Adolescents (aged 12 to 16-18 years, depending on the region) are the oldest group of paediatric 
patients. (i) The main difference to younger children is the sexual maturation. Sex hormones might 
interfere with drugs and medicinal products may delay the adolescent’s development. For certain 
drugs, pregnancy testing, review of sexual activity, as well as information about correct use of 
contraceptives becomes necessary. (ii) During adolescence, neurocognitive abilities develop further 
and body growth continues. Medicinal products that impede these developments should be used 
carefully, since they might have an impact on pubertal growth spurt affecting the final height of a 
person [194]. (iii) Hormonal changes during the development of adolescents can also influence many 
diseases such as increasing insulin resistance in diabetes mellitus patients [201] or recurrence of 
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seizures around menarche [202]. (iv) The use of recreational drugs such as alcohol [203] or 
tobacco [204] by adolescent patients might have a huge impact on concomitant medicinal products 
resulting in over- or under-dosing. 
When comparing paediatric patients with adults, the differences are not limited to drug metabolism 
and absorption but also include organs of perception, meaning their ability to smell and taste. Already 
between 2 and 6 days of age, the neonates’ olfactory ability starts to develop. This enables them to 
locate a food source and to discriminate their mother from other unknown mothers [205]. Children 
were reported to be more sensitive to taste than adults, mainly due to much higher density of taste 
pores and fungiform papillae on the tongue. Moreover, it was stated that the sense of taste is 
developing during childhood, being not yet completely mature in 8 to 9 year old children [206]. 
Therefore, palatability testing in adults cannot replace palatability testing in children. How palatability 
can be tested in children is described in more detail in section 1.4.3. 
 
1.4.2 PAEDIATRIC FORMULATIONS 
From the information about paediatric age groups, which was outlined above, it becomes clear that 
children are not small adults. At the moment there is a lack of medicinal products available as 
paediatric friendly formulations and tested for use in children [194]. So far, paediatricians need to 
prepare and administer unlicensed formulations by manipulating adult dosage forms (“off-label use”). 
This includes splitting or crushing tablets, opening capsules, dispersing tablets or capsules in liquids 
and taking proportions of them, cutting suppositories, or applying injectable solutions by other routes. 
It is obvious that such manipulations might have huge impact on bioavailability and safety of a 
medicinal product [199]. To improve the quality, efficacy, and safety of paediatric medicines, age-
appropriate formulations of medicinal products for use in children are necessary. Already in 2001, the 
European Medicines Agency (EMA) recommended to test paediatric formulations in children [199, 
207]. In addition to deeper and more exact information on the consequences of off-label use, the 
manufacturers were asked to perform paediatric investigations with the products intended for 
paediatric use. This so called Paediatric Investigation Plan (PIP) has been required by EU paediatric 
regulations since 2006, including an overview of planned measures or performed studies before 
authorising a drug for use in children [199]. One main aim was that children will gain access to 
medicinal products with a positive risk-benefit balance [191]. 
The development of age-appropriate formulations for children is challenging due to different aspects. 
Child friendly medicines have to allow for accurate dosing and need to show good palatability to 
support patient’s compliance with the therapy [207]. Therefore, liquid or small particulate dosage 
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forms are preferred for children [208]. So far, there is not much known about the acceptability of 
different dosage forms, administration volumes, dosage form size, taste, and acceptability as well as 
safety of excipients with regard to age and developmental status of the child [199]. Interregional 
differences make it necessary to produce different types of formulations, flavours, and colours. 
According to different age classes, several galenical formulations may be needed, such as liquids, 
suspensions, or for example chewable tablets. Moreover, all these formulations need to exist in several 
drug concentrations keeping the aforementioned paediatric age groups in mind [207]. To be 
considered child-appropriate, a medicinal product needs to address following criteria [208]:  
(I) To achieve sufficient bioavailability the site and route of absorption and the properties of the drug 
formulation need to be kept in mind. For children, the main route of administration is per os [192, 
200]. Important points to consider when administering a peroral drug are varying gastrointestinal 
transit times, incomplete intestinal drug absorption, changing pH conditions along with the passage 
through the GIT, drug-food interactions, instability of the drug under gastric conditions, and the first-
pass effect. As already mentioned in section 1.4.1, the gastric fluid of newborns and infants is in an 
almost neutral pH range. It takes one year until infants have a pH of 1-2 at fastened state, which is the 
normal value for grown-ups. This makes enteric coatings inappropriate for infants under 1 year. 
Moreover, the transit time through the GIT might deviate a lot from adults. Alternatives to the peroral 
administration are rectal, buccal, transdermal, nasal, inhalative, or parenteral administration routes. 
However, bioavailability remains a challenge in all these formulations and their advantages must be 
balanced against their drawbacks to find the optimal formulation for every single patient [192, 208]. 
(II) To be considered as safe, excipients need to be non-toxic, inert, non-allergenic, and form non-toxic 
metabolites in the body of a child [208]. It has to be kept in mind that not every excipient, which is safe 
in adults, can be chosen for paediatric formulations [195, 209]. To gain more information on 
substances, which are suited for paediatric formulations and which ones have to be omitted, European 
and US Paediatric Formulation Initiatives teamed up. They created a database to collect and easily 
access relevant information about Safety and Toxicity of Excipients for Paediatrics (STEP) [209–211]. 
With regards to toxicity, solid oral dosage forms are preferable against liquid formulations, which 
require more often potentially toxic excipients. On the other hand, dose administration and adaption 
are easier with liquid formulations. It becomes more and more obvious that it is necessary to balance 
many different factors when formulating medicines for children [208]. 
(III) Palatability and acceptability of a medicinal formulation are important parameters to be 
considered when treating children. In a Danish study, almost half of the children receiving liquid or 
solid oral dosage forms had difficulties in taking their medication. Main problems, parents and 
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caregivers were facing when administering oral formulations, were taste of the medicine and 
difficulties of children in swallowing solid medications. The younger the children, the more pronounced 
the difficulties were [212]. Bad palatability may result in poor adherence ending up in treatment 
failure, complications, and eventually the development of drug resistance [213]. To improve 
acceptance, possible options include dispersing small-sized pellets in food or juices and offering 
training in swallowing tablets to children [208, 214]. 
(IV) Another key factor to be considered when formulating medicines for children is an adequate dose 
uniformity. Liquid formulations have the advantage to be easily adjustable by volume adaption. 
However, a certain level of accuracy and training is necessary to ensure exact dosing [215]. 
Unfortunately, many dosing devices for liquid formulations are not very exact [216]. When it comes to 
solid dosage forms the difficulties further increase. Splitting is less accurate and special coatings 
around the tablets might be destroyed by crushing or cutting [217]. To overcome these problems, 
multiparticulate systems such as pellets, micropellets [218], or minitablets [219] have been developed. 
These cover broad dosing ranges and can be safely and easily tailored to individual patients’ needs. 
(V) To make a medicinal product efficient, easy and safe administration are very important points to 
be reflected. Medication errors can happen at any time of the application process. Typical mistakes 
are incorrect dosage or frequency of drug administration, prescription mistakes, wrong route of 
administration, interactions with food or other drugs, or inadequate communication between 
medicinal personal, parents, and other caregivers [220]. To reduce these pitfalls, buccal drug 
formulations present an attractive alternative to classic oral dosage forms by combining easy 
administration with the advantages of solid formulations such as drug stability and non-toxic 
excipients [208]. Moreover, e-prescribing, medication reconciliation, barcode systems, clinical 
pharmacists in medical settings, improved training of medicinal staff, standardisation of equipment 
used by laypersons, precise and clear product information and clear package design are needed to 
overcome sound-alike and look-alike confusions [208, 220]. 
(VI) The socio-cultural acceptability of medicinal products must be considered to avoid stigmatisation 
of patients. Therefore, drug administration should be – where possible – adjusted to the daily life 
making use of controlled release formulations or delivery systems facilitating drug administration also 
in school environments [199]. Moreover, preferences regarding galenical formulations should be 
respected to enhance patient adherence [208]. 
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1.4.3 PAEDIATRIC PALATABILITY TESTING 
As mentioned above, palatability and acceptability of a medicine are important parameters to be 
considered when treating children. So far, there has not been much systematic methodological 
research on how to evaluate taste and mouthfeel of age-appropriate formulations in paediatric patient 
populations. To assess the acceptability of a medication, taste and smell can be evaluated 
quantitatively by using indirect analytical methods and taste/smell sensors. Moreover, a qualitative 
analysis is possible by taste panels, also called consumer testing. It is known that adults and children 
have different sensory feelings [205, 206]. Therefore, the EMA considers children the most suitable 
target population for taste assessment of paediatric formulations [199]. However, children are a very 
vulnerable patient population and should only be considered for clinical trials if research cannot be 
performed with adults. If research with children is unavoidable, the least vulnerable patient 
population, i.e. older children, should be included. In all cases, the decision should be based on target 
population, possibility of extrapolation, and the scientific validity of the planned approach [221]. The 
EMA clearly states that “in principle, healthy children should not be enrolled as healthy volunteers, 
because they cannot consent and are vulnerable like children with a disease or condition. […] 
Exceptions could be where healthy children participate in palatability testing such as swill and spit taste 
testing for a new flavoured medicine” [221]. 
When planning a clinical trial with children, it is necessary to adapt the methods to the child’s 
developmental stage and to focus on practical and ethical considerations and limitations [222]. 
According to the EMA, key elements to consider before designing a palatability study are that 
(i) children have a shorter attention span, and therefore the test should be as short as possible. 
(ii) Children are easily diverted with other things than the trial. This makes it necessary to design and 
perform the trial as motivating as possible and to give the children the impression of having fun during 
the trial. (iii) It is very important that every child participating in the trial can understand the procedure. 
The researcher is asked to describe the procedures to the children as child friendly as possible, e.g. by 
using cartoons. (iv) Children are easily confused and become taste-fatigue if there are too many 
variables during a trial. Therefore, variables should be limited to a maximum of four. Generally, the 
EMA considers children older than 4 years as capable of participating in taste trials. The key 
characteristics of children, which were mentioned above, are the more prominent the younger the 
child is. This results in failure rate variations up to 50% for younger children, depending on the design 
and duration of the test. Moreover, younger children have difficulties in communicating their feelings 
and preferences [199]. 
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Amongst others, there are two common principles to evaluate palatability of a formulation in children: 
verbal judgement and facial hedonic scales (FHS, Figure 8 A). Children younger than 5 years seem to 
be less capable to express taste preferences and differences between test formulations compared to 
older children. To obtain reliable estimation of taste acceptance in younger children, the verbal 
method is preferred over the FHS [223]. This means, when asked for sensory experience, children will 
be able to state whether they had liked the probe substance or not, referring to their acceptance of a 
taste. But when it comes to preferences between several formulations they might be overstrained in 
discriminating between taste, after-taste, texture, smell, or appearance of the formulation. Moreover, 
Davies and Tuleu concluded that children from 3 years on are capable of using an FHS, whereas visual 
analogue scales (Figure 8 B) are more widely applied for children older than 6 years [222]. In addition, 
the facial expression of the volunteer himself may help to gather more information on the acceptance 
of the tested formulation. Reliability of the outcome might be further increased by involving parents, 
guardians, or health providers. The EMA suggests asking them about any discomfort or other 
observations in relation to the acceptance of the study medication by their children [221]. 
 
Figure 8. Tools commonly used to rate perception of children. These are well-established for paediatric pain 
assessment. A) Facial hedonic scale, FHS. The child should point at the face that describes its feelings the best. 
On the backside each face is linked to a number (often between 0 to 10), which can be used for evaluation by 
clinicians. B) Visual analogue scale. Older children are able to rate their perception directly in numbers. They are 
asked to point out which number describes best what they feel at the moment (e.g. from “no pain” 
corresponding to 0 to “unbearable pain” corresponding to 10). Figures were adapted from [224]. 
 
In the herein presented work, the palatability of an oral disintegrating tablet (ODT) in 40 children (aged 
2 to 10 years) attending the outpatient department at University Children’s Hospital of Basel (UKBB) 
for minor surgical ailments was tested. The ODT has been evaluated before in adult volunteers, 
showing very good acceptability and palatability [225]. But as already outlined above, it is necessary 
to perform palatability testing of paediatric formulations in paediatric patients. Therefore, a 
palatability assessment of these placebo ODTs was conducted in children who were divided according 
to the age classes defined in section 1.4.1: pre-school children were aged 2 to 5 years and the older 
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population was 6 to 10 years old. Keeping in mind the difficulties of younger children to communicate 
preferences between several formulations, the focus was on acceptance of the palatability of the test 
formulation. The younger children were asked child appropriate questions and their spontaneous 
verbal judgement was recorded. For the older subpopulation these questions were combined with an 
FHS. In addition, the parents of every child were asked to compare drug formulations – which they are 
already familiar with – with the ODT. It was of additional interest to elaborate and critically evaluate 
the suitability of the questionnaire to generate data about palatability in healthy children. 
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Supporting information 
PDMS-b-PMOXA polymersomes for hepatocyte targeting and assessment of toxicity 
 
Encapsulation of Carboxyfluorescein and Release Profile 
The polymersomes were loaded with Carboxyfluorescein (CF) as described in section 2.6 of the article. 
The release profile of CF in buffers containing naturally occurring serum protein was evaluated: CF 
release was tested in 3% BSA in DPBS and in 50% FCS in DPBS for 48 h at 37°C. 
 
Figure S1. Release profiles of PP-CF in buffers containing naturally occurring serum protein. The release profiles 
of CF in 3% BSA are represented by black triangles, the release of CF in 50% FCS is shown with open circles, and 
the black squares depict the release of CF in DPBS. SD is shown with error bars (n = 3), *p < 0.01. 
 
Fluorescence Correlation Spectroscopy 
Fluorescence correlation spectroscopy (FCS) measurements were performed as described 
elsewhere [1] with an inverted Zeiss 510-Meta/Confocor2 laser-scanning microscope (Carl Zeiss AG, 
Feldbach, Switzerland) equipped with an argon laser (488 nm) and a water immersion objective (Zeiss 
C-Apochromat 40x, NA 1.2). 15 µL of the samples of HiLyte Fluor 488, HiLyte Fluor 488 labelled 
proteins, and polymersomes conjugated to HiLyte Fluor 488 labelled proteins were measured at RT on 
a cover glass (Huber & Co., Reinach, Switzerland). Fluctuation in fluorescence intensity was analysed 
in terms of an autocorrelation function (average of 30 measurements over 10 s). Diffusion times of the 
samples were independently measured and fixed in the fitting procedure to reduce the amount of free 
fitting parameters. Molecular brightness measurements were used to evaluate the number of HiLyte 
Fluor 488 per molecule of protein and the number of HiLyte Fluor 488 labelled protein per 
polymersome. 
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Figure S2. Fluorescence correlation spectroscopy analysis of polymersomes conjugated to HiLyte 488 
fluorescently labelled protein. A) Normalised autocorrelation curves of free HiLyte 488 (crosses), HiLyte 488 
labelled asialofetuin (AF-488, open circles), and polymersomes conjugated to AF-488 (PP-AF-488, black circles). 
Different diffusion times of free HiLyte 488 (31 µs), AF-488 (557 µs), and PP-AF-488 (2307 µs) indicated the 
successful conjugation of the polymersomes. B) Normalised autocorrelation curves of free HiLyte 488 (crosses), 
HiLyte 488 labelled fetuin (F-488, open circles), and polymersomes conjugated to F-488 (PP-F-488, black circles). 
Different diffusion times of free HiLyte 488 (31 µs), F-488 (308 µs), and PP-FF-488 (2315 µs) indicated the 
successful conjugation of the polymersomes. Autocorrelation curves represent the averages of 
30 measurements over 10 seconds. 
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Supporting information 
Self-assembling chitosan hydrogel: a drug delivery device enabling sustained release of proteins 
 
Experimental section 
Materials and equipment 
N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDAC) was supplied by Carl Roth 
GmbH (Karlsruhe, Germany). Bovine serum albumin (BSA), chitosan from shrimp shells (C3646) and 
thioglycolic acid (TGA) were purchased from Sigma-Aldrich (Buchs, Switzerland). 4-maleimidobutyric 
acid and N-hydroxysuccinimide (NHS) were obtained from TCI Europe N.V. (Zwijndrecht, Belgium). All 
other chemicals were of analytical grade as well and used as obtained. Milli-Q water with a resistivity 
of 18.2 MΩ/cm was obtained with a Milli-Q Advantage A10 System, purchased from Millipore (Billerica, 
MA). Prontosan® Wound Gel and Prontosan® Wound Gel X (B. Braun Medical AG, Sempach, 
Switzerland) were purchased from a public pharmacy in Switzerland. 
 
Analysis and chemical modification of chitosan 
The molecular weight of chitosan was determined by viscosity measurement [1] and the degree of 
deacetylation was analysed by 1H NMR spectroscopy [2]. 1H NMR spectra were recorded on a Bruker 
Avance III spectrometer operating at 500.13 for 1H, equipped with a 5 mm BBI probe with a z-gradient. 
The spectra were measured in a mixture of D2O/DCl (Armar Chemicals, Döttingen, Switzerland) at 70°C 
using standard Bruker pulse sequences. Spectra were processed by a Bruker TopSpin 3.0 software. 
Modification of chitosan was performed according to the literature procedure [3]. Maleimide coupling 
was achieved as follows: To 50 mL of a 0.5% (wt/vol) solution of chitosan in Milli-Q water (pH adjusted 
to 5.5 with 1 M hydrochloric acid (HCl)), 4-maleimidobutyric acid, dissolved in dimethylsulfoxide 
(80% wt/vol), was added resulting in a concentration of 0.8% (wt/vol). EDAC and NHS were added in 
the same molarity as 4-maleimidobutyric acid. To obtain maleimide-chitosan, the reaction was stirred 
overnight at room temperature (RT). To thiolate chitosan, 1.1 vol% of TGA was added to 50 mL of a 
0.5% (wt/vol) chitosan solution (pH 5.5) and EDAC and NHS were added in the same molarity. The 
reaction was stirred overnight at RT. Purification of both modified polymers was performed by 
extensive dialysis (molecular weight cut off (MWCO) 14 kDa) against 5 mM HCl at 4°C. Subsequently, 
maleimide-chitosan and thiolated chitosan were recovered by freeze drying (Christ Epsilon 2-6D, Adolf 
Kühner AG, Birsfelden, Switzerland).  
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Qualitative Infrared analysis (FTIR, ALPHA equipped with a single reflection ATR module, Bruker Optik 
GmbH, Ettlingen, Germany) was carried out with lyophilised samples of the modified chitosan 
compared to unmodified chitosan. Spectra were recorded in the middle infrared (4500 cm-1 to 
400 cm-1) with a spectral resolution of 4 cm-1 in the absorbance mode for 64 scans at RT. Spectra were 
processed by a Bruker OPUS/Mentor software. 
 
Formation of chitosan hydrogel 
40 mg/mL of lyophilised thiolated chitosan and 18 mg/mL of lyophilised maleimide-chitosan, 
respectively, were dissolved in Dulbecco’s phosphate-buffered saline (PBS), pH 7.4. The solutions were 
formed under stirring overnight at RT. Afterwards they were mixed in a 1:1 ratio, referred to the weight 
of lyophilised chitosan, and allowed to crosslink overnight at RT.  
 
Analysis of the chitosan hydrogel 
For the analysis of the surface morphology by scanning electron microscopy (SEM), the hydrogels were 
lyophilised, glued on an aluminium sample holder and sputtered with 20 nm gold (Leica EM ACE 600 – 
Double Sputter Coater, Leica Microsystems, Wetzlar, Germany). Pictures were conducted using a Nova 
NanoSEM 230 (FEI, Hillsboro, OR) with an acceleration voltage of 5 kV, a magnification of 4691x, 
6.9 mm working distance, a spotsize of 2.5, mode SE and scanmode ETD. 
Rheology measurements were conducted with a cone-plate Haake Mars 40 Rheometer (Thermo Fisher 
Scientific Inc., Cambridge, UK). The cone had a diameter of 20 mm and an angle of 1° (gap 0.048 mm). 
Rotational viscosity was measured at 20°C by linearly increasing the shear rate from zero to 200.0 s-1 
during 60.0 s followed by 30.0 s of rotation at a shear rate of 200.0 s-1 and again 60.0 s of linearly 
decreasing shear rate down to zero.  
The spreadability of the hydrogel was measured according to Münzel et al. [4] using Equation S1, 
where d is the average of the diameter of the gel’s surface under a certain weight. The spreadability 
of commercially purchased Prontosan® Wound Gel and Prontosan® Wound Gel X was compared to the 
spreadability of our chitosan hydrogel. 
𝑠𝑝𝑟𝑒𝑎𝑑𝑎𝑏𝑖𝑙𝑖𝑡𝑦 = 𝑑2 ∗ 𝜋/4           (Equation S1) 
Swelling and degradation properties of the hydrogel were examined in PBS pH 7.4, acetic buffer pH 5 
and a 1 mg/mL lysozyme solution. The weight was measured at certain time points by taking the gels 
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out of the medium, gently removing excess of water and weighing afterwards. Subsequently, the gels 
were placed back into the medium again.  
To test the protein release, the chitosan hydrogel was loaded with 1.8% (wt/vol) BSA. The release was 
monitored using a micro dialysis approach (MWCO 300 kDa). The dialysis was carried out against PBS, 
pH 7.4 and pH 8.0, for 32 hours at RT. To measure the BSA concentration, 1 mL of medium was taken 
out at certain time points and placed back into the medium after measurement to keep constant 
volume. By using UV-Vis spectroscopy (Bucher Biotec AG, Basel, Switzerland) the concentration of 
released BSA was determined. FDA “Guidance for Industry” was used to calculate the similarity 
factor f2 (Equation S2) where n is the number of time points, Rt is the release value of the reference 
gel at time t, and Tt is the release value of the compared gel at time t. For curves to be considered 
similar, f2 values greater than 50 (50-100) ensure sameness or equivalence of the two curves and, thus, 
of the performance of the two products [5]. 
𝑓2 =  50 ∗ log {(1 + (
1
𝑛
) Σ𝑡=1
𝑛 (𝑅𝑡 − 𝑇𝑡)
2)
−0.5
∗ 100)}      (Equation S2) 
To determine statistical significance, one-way analysis of variance (ANOVA) followed by Bonferroni’s 
post hoc test using statistical software of OriginPro 2016 (OriginLab Corporation, Northampton, MA) 
was performed, p < 0.01. The same software was used for curve fittings, based on Equation 1. 
 
Figure S1. FTIR spectra of A) of unmodified chitosan, B) maleimide chitosan, and C) thiolated chitosan. 
  
59 
Results – Self-assembling chitosan hydrogel: a drug delivery device enabling sustained release of proteins – SI 
 
 
Figure S2. Linear regression of cumulative release profiles of BSA versus square root of time. Black squares 
represent the pre-loaded gel, which was used directly for release testing (gel 1). The pre-loaded and lyophilised 
gel (gel 2) is shown with open squares. The open triangles depict the values of release from the post-loaded 
chitosan hydrogel (gel 3). For detailed description of the formulations please see Figure 4c-e and Table 1. 
 
References 
1. G. A. Morris, J. Castile, A. Smith, et al (2009) Macromolecular conformation of chitosan in dilute solution: A 
new global hydrodynamic approach. Carbohydr Polym 76(4):616-621. doi:10.1016/j.carbpol.2008.11.025 
2. M. Lavertu, Z. Xia, A. N. Serreqi, et al (2003) A validated 1H NMR method for the determination of the degree 
of deacetylation of chitosan. J Pharm Biomed Anal 32(6):1149-1158. doi:10.1016/S0731-7085(03)00155-9.  
3. C. E. Kast, A. Bernkop-Schnürch (2001) Thiolated polymers – thiomers: development and in vitro evaluation 
of chitosan-thioglycolic acid conjugates. Biomaterials 22(17):2345-2352. doi:10.1016/S0142-
9612(00)00421-X. 
4. K. Münzel, J. Büchi, O.-E. Schultz (1959) Galenisches Praktikum. Wissenschaftliche Verlagsgesellschaft m.b.H. 
Stuttgart 
5. U.S. Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug 
Evaluation and Research (CDER) (1997) Guidance for industry – dissolution testing of immediate release solid 
oral dosage forms. 
  
60 
Results – Self-assembling chitosan hydrogel: a drug delivery device enabling sustained release of proteins – SI 
 
 
61 
Results – Microdosed midazolam for the determination of CYP  3A activity: development and clinical evaluation 
of a BF 
2.3 MICRODOSED MIDAZOLAM FOR THE DETERMINATION OF 
CYTOCHROME P450 3A ACTIVITY: DEVELOPMENT AND CLINICAL 
EVALUATION OF A BUCCAL FILM 
Klara Kiene1, Noriyuki Hayasi2, Jürgen Burhenne3, Ryo Uchitomi2, Claudia Sünderhauf4, Yasmin Schmid4, 
Manuel Haschke4,5, Walter Emil Haefeli3, Stephan Krähenbühl4, Gerd Mikus3, Hirohiko Inada2, Jörg 
Huwyler1 
1 Department of Pharmaceutical Sciences, Division of Pharmaceutical Technology, University of Basel, 
Klingelbergstrasse 50, 4056 Basel, Switzerland 
2 Kyukyu Pharmaceutical Co., Ltd., 32-7 Hibari, Imizu City, Toyama 939-0351 Japan 
3 Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Im 
Neuenheimer Feld 410, 69120 Heidelberg, Germany 
4 Clinical Pharmacology & Toxicology, University Hospital Basel, Schanzenstrasse 55, 4031 Basel, 
Switzerland 
 
European Journal of Pharmaceutical Sciences 2019, 135, 77-82. doi:10.1016/j.ejps.2019.05.010 
 
 
 
  
62 
Results – Microdosed midazolam for the determination of CYP  3A activity: development and clinical evaluation 
of a BF 
 
 
63 
Results – Microdosed midazolam for the determination of CYP  3A activity: development and clinical evaluation 
of a BF 
 
 
64 
Results – Microdosed midazolam for the determination of CYP  3A activity: development and clinical evaluation 
of a BF 
 
 
65 
Results – Microdosed midazolam for the determination of CYP  3A activity: development and clinical evaluation 
of a BF 
 
 
66 
Results – Microdosed midazolam for the determination of CYP  3A activity: development and clinical evaluation 
of a BF 
 
 
67 
Results – Microdosed midazolam for the determination of CYP  3A activity: development and clinical evaluation 
of a BF 
 
 
68 
Results – Microdosed midazolam for the determination of CYP 3A activity: development and clinical evaluation 
of a BF – SI 
Supporting information 
Microdosed midazolam for the determination of cytochrome P450 3A activity: development and 
clinical evaluation of a buccal film 
 
Recruitment of healthy volunteers 
Healthy volunteers were recruited considering inclusion and exclusion criteria (Table S1) after pre-
study clinical, medical, and laboratory examinations (Table S2). 
Table S1. Inclusion and exclusion criteria for volunteers participating in the pharmacokinetic study. 
Inclusion Criteria 
Healthy male or female subjects, 18-50 years, BMI 18.0-29.9 kg/m2. Ability to understand and willingness to comply  
with study interventions and restrictions.  
Signed informed consent after full explanation of the study to the participant. 
Physical and mental health; medical assessment determined by medical history, physical examination, especially 
ECG, and laboratory evaluation shows no clinically relevant abnormalities.  
Normal renal function and normal liver blood tests (minor deviations of laboratory values from normal range are  
acceptable, if judged by the investigator to be of no clinical relevance). 
Females of child bearing potential are only included if using reliable contraception with a Pearl Index <1% (i.e. two  
independent effective contraceptive methods) during the study and 1 week after the last administration of study 
medication. 
 
Exclusion Criteria 
Any regular drug treatment within the last two weeks, except for oral contraceptives.  
Exclusion of the trial due to irregular drug treatment or regular substitution of endogenous substances, minerals, and  
trace elements will be decided on an individual basis (considering the potential impact on CYP3A activity and drug 
absorption). 
Any intake of a substance known to induce or inhibit drug metabolising enzymes or transport system enzymes within 
a period of less than 10 times the respective elimination half-life or 3 weeks (whatever is longer).  
Any participation in a clinical trial within the last four weeks before inclusion.  
Blood donation within 4 weeks before the trial or hemoglobin ≤11 g/dL.  
Vaccination (active or passive) within one month before inclusion into the trial.  
Any physical disorder that could interfere with the participant’s safety during the clinical trial or with the study  
objectives.  
Any acute or chronic illness, or clinically relevant findings in the pre-study examination.  
History or clinical evidence of any disease or medical condition, which may interfere with the pharmacokinetics of  
midazolam or which may increase the risk for toxicity or adverse events. 
Allergies (except for mild forms of hay fever) or history of hypersensitivity reactions.  
Active liver disease.  
Regular smoking (≥5 cigarettes/week).  
Excessive alcohol drinking (>20 g alcohol/day).  
Inability to communicate well with the investigator due to language problems or poor mental development.  
Inability or unwillingness to give written informed consent.  
For female participants: pregnancy or lactation. 
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Table S2. Medical Examination of the volunteers prior to participation. 
Medical Examination 
Medical history. 
Physical examination including measurement of height and weight, blood pressure, pulse rate and temperature, a  
review of organ systems including lungs, heart, abdomen, liver, kidneys, and peripheral pulses, eyes, nose, throat, 
skin, and short neurological status.  
12-lead electrocardiogram.  
Safety laboratory screening (red blood cell count, haematocrit, haemoglobin, white blood cell count with differential  
(neutrophils, eosinophils, basophils, monocytes, and lymphocytes), AST, ALT, AP, CK, total bilirubin, creatinine, total 
protein, albumin, INR, electrolytes (sodium, potassium, calcium, chloride).  
Urine analysis: chemical testing by a strip.  
Urine screening for illicit drugs.  
Qualitative urine pregnancy test in female participants. 
 
Stability of the buccal film 
Stability tests were performed under stress conditions at 60°C. Results from the stress tests are 
summarised in Table S3. 
Table S3. Stability testing of the midazolam-containing buccal film at 60°C for up to 3 weeks. 
Storage condition Outer appearance Midazolam content  
(%) 
Water content  
(%) 
Color difference 
(⊿E * ab) 
Initial white film 
preparation 
99.4 3.88 - 
60°C – 1 week white film 
preparation 
96.7 3.21 0.38 
60°C – 2 weeks white film 
preparation 
96.5 3.35 0.68 
60°C – 3 weeks white film 
preparation 
96.1 3.32 0.94 
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2.4 ORAL DISINTEGRATING TABLETS BASED ON FUNCTIONALISED CALCIUM 
CARBONATE: A PALATABILITY STUDY IN CHILDREN FROM 2 TO 10 YEARS 
 
Manuscript under preparation, to be submitted to Archives of Disease in Childhood 
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Key Points 
Question: Are orally dispersible tablets acceptable for oral administration of medications to preschool 
and school-age children? 
Findings: In this cross-sectional study that included 40 children aged 2 to 10 years, a single dose of an 
orally dispersible placebo carrier tablet was deemed to be highly acceptable by 93% of parents and 
staff, and had even higher acceptability (97%) based on observation of the participating children. 
Meaning: Greater use of this or similar child-appropriate solid oral formulations could improve access 
to high-quality medicines and adherence for children globally. 
 
Abstract 
Importance: Despite offering advantages for stability and handling, very few solid oral formulations 
appropriate for young children are available. 
Objective: To evaluate the acceptability of a novel oral dispersible tablet formulation for 
administration to preschool and school-age children. 
Design: Cross-sectional acceptability study of a novel child-appropriate monolithic calcium carbonate 
based orally dispersible placebo carrier tablet.  
Setting: Outpatient surgical and fracture clinic of a Swiss university children’s hospital.  
Participants: Children aged 2 to 10 years without underlying diseases and not wearing fixed dental 
braces were eligible. Children indicating their verbal assent to take part and for whom parents provided 
their written informed consent to participation were recruited.  
Exposure: One orally dispersible placebo carrier tablet (5 mm diameter) was administered by a 
member of the research staff to each participating child by placement on the tongue or into the buccal 
pouch. 
Main outcomes and Measures: Acceptability was rated by parents on a 5-point Likert scale (“very 
acceptable” to “completely inacceptable”), and by research staff on a 4-point acceptability scale (“child 
wants to try tablet” to “refusal”). Child behaviour and responses were observed to identify poor 
acceptability.  
Results: In total, 40 children (2-5 years of age, n=20; 6-10 years of age, n=20) were included in the 
study. The orally dispersible placebo carrier tablet had a very high acceptability. The majority of 
parents reported the formulation to be acceptable or very acceptable (37/40, 93%). For the same 
children, staff reported administering the orally dispersible tablet without problems. Parents whose 
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children had previously received oral medications, 13/35 (37%), reported difficulties in administering 
conventional marketed child-appropriate formulations. The orally dispersible tablet was reported to 
be easier to administer by 27/35 (77%) parents. None of the children showed distress on receipt of the 
tablet and only 1/40 children spat out the tablet. 
Conclusion and Relevance: A novel oral dispersible placebo carrier tablet was reported to be highly 
acceptable for administration to preschoolers and school-age children by parents and healthcare staff. 
Due to advantageous physiochemical properties, this and similar formulations may simultaneously 
improve access to high-quality medicines and adherence for children globally. 
 
Introduction 
Among paediatric patients, medication palatability is essential for patient acceptance, therapeutic 
compliance and successful outcome of a therapy [1, 2]. Oral dosage forms are preferred to treat 
children [3]. A medication’s taste and the ability of children to swallow their medicine may greatly 
influence the selection of a drug, therefore therapy and prescribing practice. Despite offering 
advantages for stability and handling, very few solid oral dosage formulations appropriate for young 
children are available. Most of the drugs on the market are authorised only for adult use [4]. Therefore, 
paediatricians need to prepare and administer unlicensed formulations by manipulating adult dosage 
forms (“off-label use”). This includes splitting or crushing tablets, opening capsules, dispersing tablets 
or capsules in liquids and taking proportions of them, cutting suppositories, or applying injectable 
solutions by other routes. However, such manipulations might extremely influence bioavailability and 
safety of a medicinal product [5]. Additionally to deeper and more exact information on the 
consequences of such manipulations, the manufacturers are asked to perform paediatric 
investigations with the products intended for paediatric use [5]. Formulating medicines for children is 
challenging due to different aspects. Paediatric formulations have to allow for accurate dosing and 
show good palatability to support patient’s compliance with the therapy [6]. So far, there is not much 
known about the acceptability of different dosage forms, administration volumes, dosage form size, 
taste, and acceptability and safety of excipients with regard to age and developments status of the 
child [5]. Different age classes and interregional differences make it necessary to produce different 
types of galenical formulations in several drug concentrations, flavours, and colours [6, 7].  
When planning a clinical trial with children it is necessary to adapt the methods to the child’s 
developmental stage, and to focus on practical and ethical considerations and limitations [8]. 
According to the EMA, palatability studies for children should be short, entertaining, easily 
understandable and with as little variables as possible. The younger the children, the more important 
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it is to respect these principles. Moreover, it has to be kept in mind that younger children have 
difficulties in communicating their feeling and preferences. Generally, the EMA considers children 
older than 4 years as capable of participating in taste trials [5]. 
Speaking of solid oral dosage forms for children, orally dispersible tablets (ODTs) are very interesting 
formulations [9]. The palatability of a novel oral dispersible tablet formulation based on Functionalised 
Calcium Carbonate (FCC) was already assessed in adults, showing good acceptability, pleasant taste 
and no bad sensations during administration [10]. It remains to be tested whether the palatability in 
children is as positive as in adults, because it is not possible to transfer the findings from adults directly 
to children due to different taste and mouthfeel sensations [5, 11]. So far, there has not been much 
systematic methodological research on how to evaluate taste and mouthfeel of age-appropriate 
formulations in paediatric patient populations. This work aims to evaluate the acceptability of a novel 
placebo ODT for administration to preschool and school-age children.  
 
Subjects and Methods 
This single-centre cross-sectional observational study included 40 children attending the outpatient 
surgical and fracture clinic of the University Children’s Hospital Basel (UKBB). The children were 
between 2 years and 10 years old, as this is the target group that is most likely to benefit from an ODT 
formulation being available as an alternative to oral suspensions. The younger group (20 children) was 
aged between 2 and 5 years, the older volunteers (20 children) were 6 to 10 years old. Keeping in mind 
the difficulties of younger children to communicate preferences between several formulations, the 
focus was on acceptance of the ODT’s palatability [12]. Administration and children’s acceptance of 
the tablet was rated by research staff on a 4-point acceptability scale (from “child wants to take the 
ODT” to “refusal”) and by parents on a 5-point Likert scale (from “very acceptable” to “completely 
inacceptable”). For the older subpopulation, additional closed questions were combined with a facial 
hedonic scale (FHS, Figure 1). 
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Population Centre Test tablet Palatability assessment 
2 to 5 years, 
20 children 
UKBB outpatient surgical 
and fracture clinic 
 
single dose of a placebo, orange 
flavoured, FCC-based ODT 
1. assessment by staff 
2. parenteral evaluation 
6 to 10 years, 
20 children 
UKBB outpatient surgical 
and fracture clinic 
single dose of a placebo, orange 
flavoured, FCC-based ODT 
1. assessment by staff 
2. parenteral evaluation 
3. child-appropriate 
questions 
4. FHS 
Figure 1. Study design 
Female and male volunteers were eligible for enrolment if they were 2 to 10 years of age, indicating 
their verbal assent to take part and for whom the parents provided their written informed consent. 
Volunteers were excluded for any of the following reasons: wearing fixed dental braces; suffering from 
injuries or inflammations affecting the oral cavity or throat; suffering from dysphagia, olfactory 
impairment, kidney impairment, or hypercalcaemia; known allergy against medications; ongoing 
antibiotic treatment at the time of the study; known moderate to severe developmental delay as 
reported by the parents; participation in any other study within the 30 days preceding and during the 
study; if parents were unlikely to reliably complete the structured questionnaire or understand 
informed consent due to significant language barriers. 
Study protocol and consent forms were approved by an Institutional Ethics Committee. Each study 
consisted of an approximately 30-min visit without follow-up visits. 
Placebo ODTs with a diameter of 5 mm, containing FCC, orange aroma, citric acid, hydrogen carbonate, 
and a cyclamate/saccharine mix, were provided by University of Basel [10]. 
The participants were screened on days of routine appointments in the fracture and surgical outpatient 
clinic of the UKBB and approached during waiting times. If a child was identified to meet the inclusion 
criteria, designated and trained research staff obtained informed consent from the legal guardian and 
verbal assent from the child. After administration of one ODT onto the tongue or into the buccal pouch 
the parents were asked to complete a questionnaire together with the study personnel. A 
questionnaire developed for adult participants [10] and adapted to suit parental reporting of 
acceptability and palatability was used. The spontaneous reactions of the children (e.g. positive 
comments, spitting out of ODT, or crying,) were observed and recorded by the staff to identify poor 
acceptability. In addition, the older children were asked whether they would like to have a second 
tablet, how fast the ODT disintegrated and where residues were felt within the mouth. The latter 
answers were checked visually by the study personnel. Moreover, the older subjects were questioned 
how they had liked the ODT by pointing to the appropriate face on an FHS (Figure 2) [13, 14]. After 
finishing the assessment, children and parents were free to leave. 
76 
Results – ODTs based on FCC: a palatability study in children from 2 to 10 years 
 
0 2 4 6 8 10 
Figure 2. Facial hedonic scale (FHS) used to evaluate the taste sensation of children between 6 to 10 years. The 
children reported the face that described their experience with the ODT best, ranging from 0 (“very good”) to 10 
(“very bad”). 
 
Statistical Analysis 
The objective of the statistical analysis was to assess taste acceptance which was the primary study 
variable. Subjects were included in the palatability analyses if they satisfied the entry criteria and 
finished taste evaluation.  
 
Results 
In total, 40 children (2-5 years of age, n=20; 6-10 years of age, n=20) were included in the study. 
78 children were screened for this palatability study and 38 were excluded for several reasons: they 
did not appear at the hospital, or enough children in their age group were already included (17/78, 
22%); their parents had not enough time to participate (3/78, 4%); their parents refused to participate 
(8/78, 10%); children did not give verbal assent (1/78, 1%); no reliable communication between staff 
and parents was possible due to language barriers (4/78, 5%); children met medical exclusion criteria 
(5/78, 6%).  
The orally dispersible placebo carrier tablet had a very high acceptability. The staff reported 
administering the ODT without any problems for almost all children (39/40, 98%). The majority of 
parents reported the formulation to be acceptable or very acceptable (37/40, 93%). Parents whose 
children had previously received oral medications, 13/35 (37%), reported difficulties in administering 
conventional marketed child-appropriate formulations. The ODT was reported to be easier to 
administer by 27/35 (77%) of parents. None of the children showed distress on receipt of the tablet 
and only 1/40 children spat out the tablet.  
Using the FHS, all children of the older subpopulation (20/20, 100%) rated the palatability of the ODT 
between 0 and 2. Moreover, 80% (16/20) of them wanted to take a second ODT when asked for it. 
Evaluating the older volunteers, the mean disintegration time within the children’s mouth was 
26 s ± 21 s, reflecting very well the disintegration time assessed by the research personnel. ODT 
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residues were distributed mainly on the tongue and within the cheek pouch, but neither were they 
detected in the corners of the mouth of any child, nor did any child try to get rid of ODT residues, e.g. 
by spitting them out or communicating an urge to drink. Moreover, no unpleasant mouthfeel was 
described. No adverse events were reported. 
 
Conclusive Discussion 
The children were divided into two subgroups. It was already recommended previously to assess taste 
acceptance in children younger than 5 years by using the child’s own spontaneous verbal judgements. 
Moreover, it was suggested to involve parents by asking about any discomfort or other observations 
in relation to the acceptance of the study medication by their child. This would ensure reliable outcome 
of a palatability study with young children [12, 15]. In contrast, children older than 6 years were 
considered to be able to express acceptability using an FHS as well as verbal judgement [16, 17]. 
The mean disintegration time measured in children between 6 and 10 years was slightly longer than in 
adults (26 s vs. 22 s). This shows that the formulation of such ODT is well suited for children even if it 
is assumed that the mouth and tongue movement during administration have a big influence on the 
ODT’s disintegration time. 
Analysis of the palatability study revealed very good acceptance of an FCC-based ODT by preschool as 
well as school-aged children. Greater use of this or similar child-appropriate solid oral formulations 
could improve world-wide access to high-quality medicines and adherence for children. A palatable 
inert carrier ODT could be formulated to contain a wide range of active pharmaceutical ingredients for 
oral delivery that are currently available only as bad tasting liquid formulations or are unavailable as 
child-friendly formulations [4]. These include frequently used drugs, such as antibiotics and steroids.  
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Supporting information 
Oral disintegrating tablets based on Functionalised Calcium Carbonate: a palatability study in 
children from 2 to 10 years 
 
Data collection about safety of the ODT’s excipients 
Pharmaceutical excipients are defined as chemically and pharmacologically inactive substances serving 
the formulation’s needs. Typical classes of excipients used in solid dosage forms are fillers, binders, 
lubricants, disintegrants, coating and matrix polymers or waxes, and glidants. Excipients are often 
comprising a major part of a medicinal form. Therefore, they have to be checked for their safety and 
drug compatibility. Paediatric formulations need to be assessed especially regarding their risk for 
toxicity. Herein, application ranges of the excipients used in the taste-masked ODT formulations for 
children 2 to 10 years old are summarised. The handbook of excipients and the Food Legislation Europa 
served as reliable sources. 
(I) Calcium carbonate is generally regarded as a nontoxic material. It may cause constipation and 
flatulence and between 4 and 60 g it can result in hypercalcemia or renal impairment. Calcium 
carbonate may interfere with the absorption of other drugs from gastrointestinal tract if administered 
concomitantly [1]. It is commercially available as Calcium Sandoz® 500. For children between 1 and 
6 years it is recommended to give 500 mg calcium, that yield in the tablet to 875 mg calcium 
carbonate [2]. Calcium carbonate E 170 is authorised to be used in the category “dietary foods for 
infants for special medical purposes and special formulae for infants” with the term quantum 
satis according to the Food Legislation Europa [3].  
(II) Calcium phosphate tribasic is widely used in oral pharmaceutical formulations and food products. 
It is generally regarded as non-toxic and non-irritant at the concentrations that are used for drug 
formulations. In excessive amounts crystals may deposit in tissues. Oral ingestion may cause 
abdominal discomfort such as nausea and vomiting [1]. The Food Legislation Europa limited calcium 
phosphate (E 341) in dietary foods for infants for special medical purposes and special formulae for 
infants to 1000 mg/kg [3]. 
(III) Croscarmellose sodium is regarded as non-toxic and non-irritant excipient, mainly used as 
disintegrant in oral pharmaceutical formulations. In the UK, croscarmellose sodium is accepted for use 
in dietary supplements [1]. Following commercially available products for children contain 
croscarmellose sodium as disintegrant: Clarithromycin Basics® 250 mg/5 mL Granulat, Euthyrox® 
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25 microgram [4, 5]. Crosslinked carmellose sodium E 468 is authorised to be used in tablets up to 
5% by weight (50’000 mg/1 kg) by the Food Legislation Europa [3]. 
(IV) Citric acid is found naturally in the human body, mainly in the bone. It is commonly consumed as 
part of a normal diet. Citric acid is regarded as non-toxic excipient. Frequent and excessive 
consumption has been associated with erosion of teeth. Moreover, citric acid can enhance intestinal 
aluminium absorption in patients with impaired renal function resulting in increased, harmful serum 
aluminium levels. Therefore, patients with renal failure taking aluminium should not take citric acid 
containing products [1]. Citric acid is used in ACC® akut Junior Hustenlöser, licensed for children [6]. 
Citric acid E 330 is authorised to be used in Infant formulae with the term quantum satis according to 
the Food Legislation Europa [3].  
(V) Sodium hydrogen carbonate is used in many pharmaceutical formulations, also including 
injections, ontological, or ophthalmic preparations. Administration of excessive amounts may disturb 
the body’s electrolyte balance resulting in metabolic alkalosis or possible sodium overload due to 
metabolism of sodium bicarbonate. The amount in antacids or effervescent tablets has been sufficient 
to exacerbate chronic heart failure, especially in elderly patients [1]. Sodium bicarbonate is also called 
baking soda. It is used in effervescent tablets and ACC akut® Junior Hustenlöser [6]. Sodium hydrogen 
carbonate (E 500 (ii)) is authorised by the Food Legislation Europa to be used in dehydrated milk with 
the term quantum satis [3].  
(VI) Sodium cyclamate has been discussed controversially. The FDA banned it in 1970, but extensive 
long-term animal feeding studies and epidemiological studies in humans failed to show any evidence 
for carcinogenic or mutagenic potential of sodium cyclamate. The WHO set an estimated acceptable 
daily intake for sodium cyclamate to 11 mg/kg body weight. Sodium cyclamate is used in the product 
Algifor® Dolo Junior being widely used in all paediatric age groups. The suspension contains 2 mg/mL 
sodium cyclamate. If a 6-8 month old infant with 5 kg body weight is dosed 3 times daily with 2.5 mL 
this results in an exposure of 3 mg/kg [7]. According to the Food Legislation Europa sodium cyclamate 
is authorised under E 952 to be used in solid food supplements (e.g. capsules or tablets) in a maximum 
dosage of 500 mg/kg [3]. 
(VII) Sodium saccharine is considered a safe intense sweetener. According to the WHO limit of intake 
is 2.5 mg/kg body weight, whereas the Committee on Toxicity of Chemicals in Food, Consumer Goods, 
and the Environment defines it as up to 5 mg/kg body weight [1]. In Switzerland, sodium saccharine is 
an excipient of Convulex®, for long-term treatment of epilepsy of paediatric patients [8]. The Food 
Legislation Europa authorised sodium saccharine (E 954) as an additive in dietary foods for special 
medical purposes with the restriction of 200 mg/kg [3]. 
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(VIII) Orange aroma Givaudan permaseal was used in a novel paediatric formulation, so far not tested 
in children, but not considered as problematic either [9]. The supplier company Givaudan stated in the 
ingredients’ declaration that this aroma is suitable for all human food related to end use applications 
where flavouring is permitted. In the technical data sheet, the provider shows values of 
0.08-2.5% formulation content for Pharma purposes [10]. 
(IX) Magnesium stearate is widely used as pharmaceutical excipient and generally regarded as 
non-toxic upon oral administration. Consuming large quantities may result in laxative effects or 
mucosal irritation. In a toxicity study with rats magnesium stearate was shown to be non-toxic when 
administered orally or inhaled. It was also not carcinogenic when implanted in the bladder of mice [1]. 
Magnesium stearate is a standard lubricant, used in Euthyrox®, which is also licensed for children [5]. 
In conclusion, all the excipients used in the placebo ODT formulation are in concentration ranges 
recommended in literature. The used excipients are found in abundance in different formulations 
world-wide including paediatric medicines. 
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3 DISCUSSION 
In the chapters above, several different drug delivery devices – mainly based on polymers – were 
described. In chapters 1.1 and 2.1 it was shown how synthetic polymers such as PDMS-b-MOXA can be 
used to formulate polymeric nanoparticles. Moreover, it was explained how these polymeric vesicles 
can be targeted towards hepatocytes and which important points should be considered when 
formulating such targeted nanomedicines. Thereafter, in chapters 1.2 and 2.2, the focus was again on 
polymers, but this time on natural polymers, namely chitosan. It was described how these polymers 
can be used to formulate hydrogels and how hydrogels can serve as devices for chronic wound healing.  
Regarding clinical application, PDMS-b-PMOXA polymersomes, modified with asialofetuin to achieve 
hepatocyte targeting, are still far away from entering the clinics. The project described herein was 
mainly based on in vitro analyses and early in vivo results obtained in zebrafish embryos. The same is 
valid for the chitosan hydrogel. The method we used to formulate this hydrogel seems very promising 
for further use as it does not require potentially toxic chemicals. However, a clinical application is not 
going to happen soon in this case as well. To still get a link to clinical practice, the following sections 
(3.1 and 3.2) focus on nanoparticles and hydrogels for clinical applications in general. What is known 
so far? Which hurdles might need to be overcome? Which achievements were already made?  
Chapters 1.3, 2.3, 1.4, and 2.4 are about clinical studies with two different formulations. In chapters 1.3 
and 2.3 a BF for CYP3A phenotyping is described. It is explained why phenotyping is necessary and why 
this new formulation offers advantages against established phenotyping strategies. Chapters 1.4, 
and 2.4 are dedicated to a palatability study in children, using ODTs. Herein, focus is on the need for 
such formulations for children and which important points need to be considered when performing 
paediatric clinical studies. In the following sections (3.3 and 3.4) the potential of BFs and ODTs for 
further use in daily clinical practice is discussed, with special emphasis on paediatric patients. 
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3.1 NANOPARTICLES FOR TARGETED DRUG DELIVERY 
3.1.1 TARGETED NANOPARTICLES IN CLINICAL STUDIES 
Nanomedicines are one of the hot topics of today’s research in the field of drug delivery. One common 
definition of the term nanomedicine is “the use of nanoscale or nanostructured materials in medicine 
that according to their structure have unique medical effects” [226]. Research in this field already 
resulted in successful development of therapeutics, in vitro diagnostics, agents for diagnostic imaging, 
or medical devices [227]. To achieve clinical translation, it is important to invest adequate resources 
into preclinical research. To make preclinical research as impactful as possible, it needs to be tailored 
to the clinical approach that is finally intended from the very beginning. Thereafter, the design of 
clinical studies needs to optimally suit their purpose and it is obviously of paramount importance to 
successfully complete these studies [227]. The first nanoparticulate drug carriers were liposomes and 
in 1995, the first FDA-approved liposomal formulation entered the market: Doxil®, doxorubicin 
encapsulated into PEGylated nanoliposomes. Doxil® is a passively targeted nanomedicine, reaching its 
target cells via the EPR effect [228]. Already in the 1980s, liposomes were modified with targeting 
ligands and proposed to increase the transport of these nanocarriers to diseased tissue compared to 
unspecific drug delivery [229, 230]. However, there is still a huge gap between numerous preclinically 
evaluated targeted nanocarriers and only few entering clinical trials. Searching the website 
clinicaltrials.gov, several trials investigate for example the non-targeted paclitaxel albumin-stabilised 
nanoparticle formulation nab-paclitaxel (Abraxane®) combined with various chemotherapeutics and 
for different indications. But only few clinical trials investigate targeted nanoparticles in clinical trials: 
doxorubicin-loaded anti-EGFR immunoliposomes were successfully tested in a phase I dose-escalation 
study (NCT01702129) [231] and a phase II study is going on at the moment (NCT02833766). 
HER2-targeted PEGylated liposomal doxorubicin (NCT01304797) and liposomal formulations of a 
docetaxel prodrug targeting the EphA2 receptor were assessed with and without other anti-cancer 
drugs (NCT03076372) [232, 233]. It was also tested in a phase I study whether the novel, tumour-
targeted, systemic gene therapy agent SGT-94 could be delivered when entrapped into liposomes 
targeted to the transferrin receptor (NCT01517464) [234]. So far, no targeted liposomal carrier has 
been approved for therapy. In terms of polymeric nanocarriers, the situation is even worse with less 
clinical trials registered using polymeric nanoparticles for targeted drug delivery: one is a polymeric 
nanoparticle formulation of docetaxel, named BIND-014, targeted against the prostate-specific 
membrane antigen. It is already tested in a phase II clinical trial against different cancers 
(NCT01812746, NCT01792479, NCT02283320, NCT02479178). 
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Recently, several reviews tried to analyse why preclinical studies and clinically usable nanomedicines 
remain disconnected [235, 236]. For Rosenblum and co-workers, the main hurdles for successful 
implementation of actively targeted nanomedicines into clinical practice are physiological barriers 
such as endothelial barriers, the uptake by target cells and lysosomal escape, as well as shielding of 
the nanocarriers from the MPS. Moreover, therapeutic benefit from actively targeted nanomedicines 
is limited because of tumour heterogeneity, relative hypoxia, and hampered endosomal escape. In 
addition to physiological reasons, regulatory hurdles and complex manufacturing processes negatively 
influence the success of actively targeted nanocarriers [236].  
 
3.1.2 SUCCESSFUL HEPATOCYTE TARGETING ACHIEVED? 
In chapter 2.1 the in vitro results of targeted PDMS-b-PMOXA polymersomes are described. The 
polymersomes were designed according to the four principles mentioned in section 1.1.3 to 
successfully deliver a potential cargo to hepatocytes.  
(I) Their pharmacokinetic properties were optimised to be well suited for liver targeting. With a 
diameter around 150 nm the PDMS-b-PMOXA polymersomes would be able to pass the fenestration 
of liver sinusoids and to arrive at the hepatocytes [68]. The polymersomes’ surface charge was slightly 
negative, again ideal to reach hepatocytes [72]. Moreover, the polymersomes were stable even upon 
incubation in 3% bovine serum albumin or 50% foetal calf serum at 37°C. PMOXA was reported to add 
stealth properties to nanocarriers resulting in prolonged blood circulation times in vivo. De Vocht and 
co-workers reported that particles prepared of a triblock PMOXA-b-PDMS-b-PMOXA were neither 
cytotoxic nor did they provoke an inflammatory response by the MPS [31]. But it needs to be kept in 
mind that – according to Kierstead and colleagues – PMOXA triggered an IgM response upon injection 
into rodents even though it could prolong circulation time of the respective nanoparticles. The 
inflammatory response towards the tested polymer was comparable to results seen with PEGylated 
nanoparticles [237]. Such IgM response could result in enhanced blood clearance upon second 
injection, called accelerated blood clearance phenomenon [237–239]. In terms of the polymeric 
nanoparticles described in chapter 2.1, further investigations regarding the in vivo behaviour of 
PDMS-b-PMOXA polymersomes would be needed. Even though these polymersomes were non-toxic 
during an early screening in an in vivo model of zebrafish embryos, efficacy in an in vivo system has not 
been proven. Unpublished and preliminary results displayed that PMOXA was not capable of adding 
enough stealth properties to the polymersomes to avoid recognition by the MPS upon injection into 
zebrafish embryos.  
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(II) The target receptor for the herein described PDMS-b-PMOXA polymersomes was the ASGPR. As 
already outlined elsewhere, this receptor is well suited to target hepatocytes [66, 89]. With the 
PDMS-b-PMOXA study an efficient internalisation of targeted polymersomes into HepG2 cells via the 
ASGPR could be confirmed in vitro.  
(III) The chosen targeting ligand was asialofetuin, a ligand that is known to be selective for the 
ASGPR [78, 89]. Upon asialofetuin binding, the ASGPR is internalised via clathrin-coated pits, followed 
by endosomal fusion, and transfer to lysosomes [59]. In chapter 2.1 it was mechanistically shown that 
the internalisation mechanism of the ASGPR was not altered upon binding of asialofetuin-modified 
PDMS-b-PMOXA polymersomes. These were internalised into the early endosomes and accumulated 
in the lysosomes. As mentioned above, lysosomal escape is one prerequisite for successful clinical 
translation, because many therapeutics (e.g. nucleic acids, proteins, or peptides) will be degraded and 
inactivated under lysosomal conditions [236]. In contrast, for lysosomal storage diseases it would be 
beneficial to have drug delivery systems that transport their cargo via the bloodstream to the target 
cells and release their cargo not before entering the lysosomes. Examples for hepatic lysosomal 
storage diseases are lysosomal enzyme deficiencies (e.g. Gaucher’s disease and multiple sulfatase 
deficiency), defects in soluble non-enzymatic lysosomal proteins (e.g. Niemann-Pick disease), and 
defects in lysosomal membrane proteins (e.g. free sialic acid storage disorder) [240]. Increasing the 
activity of the defective enzyme or protein is already clinically used to treat patients with lysosomal 
storage diseases. This is called enzyme replacement therapy. Other therapy approaches aim to restore 
the equilibrium between synthesis of substrates and their degradation within lysosomes by either 
reducing the synthesis or by increasing the substrate clearance [241]. The asialofetuin-modified 
PDMS-b-PMOXA polymersomes could protect respective therapeutic enzymes from degradation and 
clearance in the bloodstream. Upon asialofetuin-targeted uptake into hepatocytes the enzyme could 
be delivered to the lysosomes where it would be needed.
(IV) The polymersomes were tested with suitable in vitro and in vivo models. Successful targeting of 
PDMS-b-PMOXA polymersomes towards hepatocytes was shown in vitro using HepG2 cells. Moreover, 
cytotoxicity of these nanocarriers was assessed in vitro as well as in vivo. For in vivo studies zebrafish 
embryos were chosen. Zebrafish embryos are increasingly used as early screening tools and to close 
the gap between cell-assays and experiments in rodents [242]. Zebrafish embryos possess several 
advantages such as small size, high reproducibility, rapid development, ex utero embryonic growth, 
and almost complete transparency until 120 hours post fertilisation. Regarding the signalling pathways 
zebrafish and human beings share a high level of genomic homology. In addition, their cardiovascular, 
digestive, and nervous systems resemble mammalian systems. This makes zebrafish embryos highly 
valuable for toxicity assessments in vivo [93, 243, 244]. 
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3.1.3 NECESSARY STEPS BEFORE ENTERING CLINICAL TRIALS 
The considerations made above reflect only the first steps in the development of a new drug 
formulation. The Nanotechnology Characterization Lab (NCL) summarised the key preclinical steps 
required by FDA before a new drug is allowed to transit from the discovery phase into clinical 
trials [245].  
(I) The preclinical characterisation contains tests for sterility and endotoxins (e.g. coagulation assays 
with Limulus Amoebocyte Lysate) to exclude misinterpretation of any data – especially immunological 
assays – due to microbial or endotoxin contaminations.  
(II) In a second step, physicochemical characterisations of the new formulation are performed. 
Therefore, size and size distribution, ligand distribution, surface charge, surface chemistry, 
composition, purity, and stability of the nanomaterials are assessed because these might influence the 
in vivo behaviour and tolerability. Moreover, batch-to-batch variability needs to be addressed and 
reduced to a minimum. The PDMS-b-PMOXA polymersomes described in this thesis were analysed 
regarding their size, size distribution, ligand distribution, surface charge, surface chemistry, and 
stability. However, scale-up of their production cycle would be very difficult. The thin-film-rehydration 
method by using a rotary evaporator is well suited for millilitre scales but not for volumes in litre-
ranges. Moreover, extrusion of larger scales might be very complex and slow. Another issue, which 
might be faced, is reproducibility of ligand binding in case several small batches would be produced 
instead of less and larger ones. Therefore, it would be worth investigating alternative production 
methods such as microfluidics, which might be more efficient to scale-up the manufacturing of 
nanoparticles [246]. 
(III) The physicochemical classification is followed by extensive in vitro assays. These biochemical 
analyses and cell-based assays are designed to mimic the in vivo conditions as close as possible. Binding 
and internalisation capacities of the nanomedicines, coagulation, plasma protein binding, haemolysis, 
and platelet aggregation upon blood contact are evaluated. Some of these assays were performed with 
the herein described PDMS-b-PMOXA polymersomes but not enough to draw final conclusions. Further 
studies would be needed.  
(IV) The in vivo characterisation suggested by the NCL is divided into three topics: pharmacology and 
toxicology, efficacy, and immunotoxicity. Pharmacokinetics (i.e. absorption, distribution, metabolism, 
and excretion (ADME)) and acute and repeated dose toxicity are determined in at least two different 
species (one rodent and one non-rodent). The results obtained from these trials are important to select 
potential starting doses for phase I clinical trials in humans. As mentioned above, toxicity screening of 
PDMS-b-PMOXA polymersomes was successfully performed in zebrafish embryos, but not in higher 
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vertebrates. Also ADME characterisations are lacking. If the efficacy of nanomedicines should be 
evaluated it is of paramount importance to use appropriate and a variety of tumour models such as 
transgenic, orthotopic, xenograft, or metastatic models in rodents. Tests for immunotoxicity consist of 
in vivo tests in rodents, assessing adjuvanticity, T-cell dependent antibody response, lymph node 
proliferation tests, and pyrogenicity assessment [245]. All these characterisations are a prerequisite 
before entering any clinical trial with human beings. Since with the PDMS-b-PMOXA polymersomes 
none of these was performed, it is obvious that this formulation is still far away from clinics.  
Even if a nanoparticulate formulation has been tested according to all the aforementioned points and 
developed to proceed into clinics, it is important to design the trials carefully. This includes distinct 
pre-selection of the patient population to choose the patients who will – most probably – benefit most 
from the new approach. To achieve best possible therapeutic outcomes, the patient pre-selections 
should focus on presence of the target receptor, the ability of the actively targeted formulation to bind 
this receptor, tumour heterogenicity, and the extent of EPR effect. It might be beneficial to use 
companion diagnostics for this purpose [66, 236]. 
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3.2 CHITOSAN HYDROGEL TO TREAT CHRONIC WOUNDS 
3.2.1 CHITOSAN FORMULATIONS USED FOR CLINICAL APPLICATIONS 
At the moment, several clinical studies are investigating chitosan scaffolds as potential material for 
wound healing: In a phase III study, the efficacy of a chitosan gel combined with isosorbide dinitrate in 
diabetic foot ulcers was investigated (NCT02789033). In another phase III study, a sponge composed 
of glycosaminoglycans and collagen ionically crosslinked with chitosan (Dermagen®) was tested 
regarding its ability heal diabetic foot ulcers (NCT00521937). Carboxymethyl chitosan (Surgi shield®) 
was successfully tested in a phase I study to achieve haemostasis immediately after endoscopic sinus 
surgery and to prevent adhesion formation (NCT01895933) [247]. Also chitosan/dextran gels were 
confirmed to be sufficient for the same purpose [248]. In a phase I study slow release Tb4 collagen and 
chitosan porous sponge scaffolds skin substitutes were evaluated regarding their efficacy and safety 
in wounds that were rated as difficult to heal (NCT02668055). Other clinical trials rated bioactive 
chitosan dressings superior to conservative treatment for ulcer treatment [249, 250]. Chitosan was 
also shown to be effective as haemostatic dental dressing (HemCon® Dental Dressing) after oral 
surgical procedures [251, 252]. Another field for chitosan is plastic surgery, where it was shown that 
chitosan dressings on skin graft donor sites fastened wound re-epithelialisation, promoted nerve 
regeneration, and led to faster return to normal skin colour than areas that were not treated with 
chitosan [253]. Moreover, a chitosan gel mixed with autologous whole blood (BST-CarGel) showed 
superior repair of cartilage lesions in the knee compared to microfracture – an articular cartilage repair 
surgical technique – alone [254]. 
There are already wound healing materials containing chitosan on the market. For example Tricol 
Biomedical Inc. sells wound dressings coated with chitosan to increase antibacterial activity 
(ChitoGauze® PRO, ChitoFlex® PRO) [255]. Medline vends a wound dressing containing chitosan and 
antimicrobial ionic silver (Opticell® Ag+), which has been shown to be effective against gram positive 
and gram negative bacteria [256]. Chitosan as haemostatic component in CELOX® has been tested in 
several clinical studies, being helpful even against life-threatening bleedings. A selection can be found 
in references [257–259]. 
 
3.2.2 DELIVERY OF GROWTH FACTORS FROM CHITOSAN SCAFFOLDS 
From these many examples above, it becomes obvious that chitosan has already made its way into 
clinics, mainly in the field of wound treatments. Often, chitosan is combined with other drugs to 
support its antimicrobial and wound healing characteristics. The drug categories that are mainly 
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delivered via chitosan scaffolds are growth factors, anti-inflammatory drugs, antimicrobial drugs, and 
other supplementary drugs advantageous for wound healing (e.g. nitric oxide) [260]. The chitosan 
hydrogel described above (chapter 2.2) was designed to deliver therapeutic proteins, for example 
growth factors. Therefore, the next section will focus on delivery of growth factors from chitosan 
systems to improve wound healing. In section 1.2.4 it was already mentioned that growth factors are 
important players for wound healing as they regulate cell growth, proliferation, migration, and 
differentiation. Moreover, chronic wounds are characterised by decreased levels of growth factors. 
This brought up the idea to provide the wound with necessary growth factors delivered via external 
wound healing materials [261, 262]. However, it needs to be kept in mind that growth factors could be 
enzymatically degraded or inactivated by the extracellular matrix after being brought into contact with 
a wound environment. Therefore, it is necessary to deliver growth factors in a wound dressing that 
protects and ensures controlled and prolonged release of its payload. 
Combining a recombinant human vascular endothelial growth factor (rhVEGF) with the antibiotic 
gentamicin in a delivery system of collagen and chitosan resulted in facilitated cell adhesion and 
proliferation. The researchers called their two-compartment structure a dermal scaffold. The two 
active compounds were encapsulated in PLGA microspheres and lyophilised. Afterwards, these were 
added to mixed solutions of collagen and chitosan and the resulting mixtures were lyophilised, too. 
The scaffold was built of two layers, containing different concentrations of loaded PLGA microspheres. 
It took more than 28 and 49 days, respectively, to release gentamicin and rhVEGF from this two-
compartment structured scaffold in vitro. These two different release times were the key characteristic 
of this delivery system. The time frame of antibiotic gentamicin release of almost one month was 
stated to be ideal during the inflammatory phase of wound healing. The two-month long release of 
rhVEGF could be helpful during remodelling by supporting vascular regeneration and skin repair. The 
dermal scaffold was successfully tested for cell proliferation capability in vitro using mouse fibroblasts. 
Moreover, antibacterial activity was evaluated by inhibiting proliferation of Staphylococcus aureus and 
Serratia marcescens [263].  
Another research group developed a sponge of chitosan and hyaluronic acid. This sponge was loaded 
with vascular endothelial growth factor (VEGF)-containing nanofibrin to deliver it to diabetic wounds. 
Chitosan and hyaluronic acid were blended and homogenously mixed with the VEGF-containing fibrin 
nanoparticles. The resulting mixture was lyophilised. VEGF was released within one week, which was 
stated as appropriate for wound dressing. The sponges were shown to be cytocompatible in vitro in 
HDF cells and HUVECs. Moreover, the angiogenic characteristics of VEGF containing scaffolds were 
determined with endothelial cells. They proliferated and formed capillary-like tubes after being seeded 
onto the chitosan sponge [264].  
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Ribeiro and co-workers presented a dextran hydrogel loaded with growth factor containing chitosan 
microparticles. Chitosan microparticles were prepared by ionotropic gelation between the anionic 
chelating agent sodium triphosphate (TPP) and cationic chitosan. Epidermal growth factor (EGF) and 
VEGF were dissolved in chitosan solutions and the microparticles were obtained by electrospinning. 
Afterwards, these were added to dextran solutions prior to crosslinking and gelation with adipic acid 
dihydrazide. Biocompatibility was shown in vitro using human fibroblasts. In vivo experiments in rats 
showed that the hydrogel containing VEGF and EGF supported the formation of moist wounds resulting 
in faster wound healing and closure than controls. Moreover, reactive or granulomatous inflammatory 
reactions in skin lesions were absent according to histological analyses [265]. 
Another option to entrap chitosan nanoparticles was described by Zhou and colleagues. They prepared 
chitosan nanoparticles loaded with recombinant human EGF (rhEGF) via ionotropic gelation with TPP. 
Afterwards, these were entrapped within a fibrin gel matrix during polymerisation, consisting of 
fibrinogen and thrombin. It was possible to deliver rhEGF via sustained and controlled release over 
more than 96 h without loss of bioactivity (as shown in vitro in BALB/c 3T3 cells) [266]. 
 
3.2.3 HOW ADVANCED IS OUR CHITOSAN HYDROGEL? 
The publications mentioned above clearly indicate the capabilities offered by chitosan based hydrogels 
in the field of wound healing and tissue engineering. Chitosan scaffolds combined with growth factors 
were shown to be biocompatible, bioabsorbable, and cell-stimulating, allowing sustained and 
controlled release of bioactive growth factors. In comparison to the hydrogel described in chapter 2.2, 
the herein presented formulations are further developed. They all contained growth factors instead of 
model proteins and all of them were at least tested in vitro, showing biocompatibility of the whole 
delivery systems. Moreover, some of them were already tested successfully in vivo, presenting 
improved wound healing characteristics, and some were even authorised for tissue regeneration 
purposes (section 3.2.1).  
However, the main focus of the work described in chapter 2.2 was the development of a hydrogel that 
is chemically crosslinked under mild and aqueous reaction conditions via Michael addition. No 
potentially toxic crosslinking agents [101] were needed and therefore, no removal of such by-products 
or excess of crosslinkers had to be performed after gelation whilst still providing the advantage of a 
strongly crosslinked hydrogel. Nevertheless, it was shown that the hydrogel was still biodegradable. 
Many chitosan delivery systems designed for wound healing make use of ionic crosslinking, as for 
example the ones described above [264–266]. Such formulations do not need crosslinking chemicals 
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but they tend to lack long-term stability and should be used only for short-term clinical 
applications [267].  
Generally spoken, many chitosan hydrogels are used after lyophilisation to be applied onto wounds. 
As already outlined in chapter 2.2, lyophilisation bears the advantage of increasing long-term stability 
and handling properties of the lyophilised product compared to a liquid or semisolid formulation. 
Moreover, a lyophilised formulation could be fixed on a wound – either using an occlusive dressing or 
a semipermeable one – with the ability to imbibe large amounts of wound exudate but not drying out 
the wound. This would result in a moist wound environment and painless dressing changes. Especially 
chronic diabetic wounds need careful observations and daily dressing changes [268, 269]. The diffusion 
mediated release of protein from the chitosan hydrogel described in chapter 2.2 was achieved within 
one day. Therefore, this would be a good candidate for wounds that need daily checking and dressings 
changes. In contrast, most hydrogels containing growth factors release their cargos over 
10-40 days [260]. By introducing ionic or covalent interactions between cargo and scaffold, release 
times would increase significantly. This would be very useful to reduce the number of dressing changes 
to a minimum and to avoid disturbance of the wound healing process by removal of wound dressings. 
To tailor the release profile of therapeutic proteins from their scaffold, different types of hydrogels 
should be chosen depending on the intended use. 
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3.3 BUCCAL FILMS FOR PHENOTYPING: A PHARMACOKINETIC STUDY 
3.3.1 PHENOTYPING IN DAILY CLINICAL ROUTINE? 
To identify variations in the enzymatic activity of CYPs, genotyping as well as phenotyping are used in 
clinical practice and are covered by EMA guidelines [270]. With these approaches, physicians try to 
individualise dose recommendations for their patients with the aim to anticipate the ones being at risk 
for therapeutic inefficacies or toxic reactions [271]. Using genotyping, the individual DNA sequence of 
each patient can be precisely determined, and functional genetic mutations coding for specific 
enzymes can be analysed. The major drawback of this approach is its inability to detect the influence 
of environmental factors on the enzymatic activity such as drug-drug interactions. For this purpose, 
phenotyping is used. It reflects a combination of genetic, endogenous, and environmental factors, 
finally providing information on the actual activity of CYPs (Figure 5) [272].  
So far, phenotyping has not been established on a clinical routine basis. Especially, for patients at risk 
such as cancer patients, this would however offer very interesting options [273]. In contrast to 
therapeutic drug monitoring, phenotyping identifies patients at risk for over- or under-treatment 
before starting a therapy, and not only during therapy. Actually, phenotyping in general would be 
beneficial for all patients. The majority of individuals might not be categorised as normal metaboliser 
for all five main CYPs (CYP3A4, CYP3A5, CYP2D6, CYP2C9, and CYP2C19), according to a retrospective 
study in more than 22’000 male and female patients, with different ethnical background, aged 
between 1 and 108 years [274]. 
Phenotyping can be performed either for one specific CYP (individual), or for multiple enzyme 
subfamilies, using a cocktail approach [275, 276]. In general, the major drawback of phenotyping 
results from possible side effects due to pharmacologically active doses of probe drugs. Therefore, the 
probability for such undesired effects needs to be reduced to a minimum by using doses as low as 
possible. The keyword here is microdosing [171, 174]. According to the EMA, a “microdose is defined 
as less than 1/100th of the dose calculated to yield a pharmacological effect of the test substance […] 
and at a maximum dose of ≤ 100 µg” [277]. As already outlined in chapter 1.3, preparation of 
microdosed formulations can be laborious and error-prone. Consequently, a new method for 
microdosing, i.e. a BF containing 30 µg of midazolam, was evaluated. The midazolam BF (chapter 2.3) 
was used for an individual phenotyping approach and might be highly relevant to phenotype patients 
who will be treated exclusively with one or even several drugs that are metabolised by CYP3A. To 
disturb the patients as little as possible, a limited sampling strategy had already been evaluated, 
reducing required blood sampling times to a minimum [190, 278]. However, there are conflicting 
reports regarding the reliability of limited sampling strategies. Masters and co-workers found that 
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partial AUCs (AUC0-1 h, AUC0-2 h, and AUC0-4 h) were not suitable to assess hepatic CYP3A activity after 
intravenous midazolam administration, neither as baseline measurement nor under inhibited CYP3A 
conditions. Only induced CYP3A activity could be predicted using such limited sampling 
approach [279]. Moreover, Mueller and colleagues retrospectively analysed data of 123 healthy 
volunteers who had received oral midazolam. They came to the conclusion that a four-sampling point 
limited sampling strategy could accurately predict oral midazolam AUC for CYP3A phenotyping, but 
not one-, two-, or three-sampling point models [280]. Therefore, further studies will be needed to 
clarify necessary prerequisites for limited sampling strategies for CYP3A phenotyping and their 
usability in clinical settings. If already for one single substance limited sampling strategies are difficult 
to achieve, it is even more problematic for phenotyping cocktails containing several probe drugs. This 
further increases patients’ discomfort during phenotyping [281]. To reduce at least the quantity of 
collected fluids like blood or urine, new sampling procedures have been investigated [282]. These 
include dried blood spots [172, 283], hair [284, 285], saliva [172], exhaled breath [286], or sweat [287]. 
Another important point to be considered when applying phenotyping cocktails are mutual 
interactions between the single components, which need to be excluded in advance [283].  
Before any phenotyping approach can be established for clinical routine, it is essential to validate it 
not only in patients with normal CYP activity, but also with inhibited and induced CYP-function [276]. 
Regarding a microdosing method such as a microdosed BF, this becomes even more important because 
CYP induction or inhibition might result in very low concentrations of parent or metabolite being 
difficult to analyse. For the method described in chapter 2.3, it is known that lower limits of detection 
are 0.093 pg/mL and 0.255 pg/mL for midazolam and 1’-OH-midazolam, respectively. It remains to be 
further evaluated whether these limits would be reached with altered CYP activities. Such studies 
would also set the range for low or high CYP activity, which could then serve as a reference for future 
applications of the substance as phenotyping probe. Another important point is to test the 
phenotyping approach in male and female volunteers [288], in older and younger patient populations, 
and in people of different weight to be able to generalise the results obtained from former 
studies [276]. 
It can be concluded that the ideal phenotyping cocktail should allow fast and simple analysis of several 
CYPs in one experiment while requiring minimal sample amounts for analysis as well as administering 
minimal doses of optimal probe drugs [289]. Keller and co-workers reviewed several different 
phenotyping cocktails and concluded that most of them show satisfactory data validation and clinical 
evidence to be used as near-future applications. Adverse reactions during therapy could be 
anticipated, improving the balance between efficacy and safety [290]. 
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3.3.2 BFS IN CLINICAL PRACTICE 
In general, thin films represent a valuable alternative to conventional drug dosage forms. Their 
advantages include being easy to swallow, self-administrable, fast-dissolving, easy to handle and 
transport, and cost-effective to develop. Systemic as well as local actions could be achieved via oral, 
buccal, sublingual, ocular, or transdermal applications [291]. 
Some drug delivery platforms based on polymeric films are already on the market: e.g. Zuplenz® oral 
soluble film (ondansetron) against opioid dependence [292], Suboxone® sublingual film 
(buprenorphine and naloxone) against nausea and vomiting [292], Breakyl® Buccalfilm (fentanyl) for 
opioid therapy [293], or Zolmitriptan RapidFilm® (zolmitriptan) against migraine [294]. It is assumed 
that the market for BFs is going to substantially grow in the near future [295, 296]. 
 
3.3.3 POTENTIAL APPLICATIONS FOR A MIDAZOLAM BF BEYOND PHENOTYPING 
As already outlined, BFs are easy to swallow and hard to be spat out. This makes them especially 
interesting for patients with dysphagia, such as paediatric, geriatric, or bedridden patients, as well as 
non-cooperative ones. The difficulties encountered when tablets or capsules must be swallowed could 
be circumvented. Patient safety would be increased by avoiding the risk of choking. Another advantage 
is that BF administration does not require additional water. This makes BFs convenient to be consumed 
anytime anywhere. Moreover, patients with repeated emesis, mental disorders, or motion sickness 
seem to prefer dosage forms that can be administered without drinking large amounts of water and 
without swallowing [183].  
In Switzerland, midazolam can be obtained as intravenous or intramuscular injection solution, rectal 
solution, or filmtablets with a size of at least 11.6 mm x 61 mm [176, 297]. Even if Dormicum® film 
tablets can be crushed and suspended to be applied as liquid or semisolid formulation [298] this is an 
inconvenient alternative. In Germany, there are midazolam solutions for buccal application in cases of 
seizures [299]. It is also possible to dilute injection solutions for oral application or to prepare 
midazolam nasal sprays. However, this is always work-intensive and error-prone. A ready-to-use 
formulation, in several midazolam concentrations, easy and safe to apply would be highly desirable. 
Therefore, a midazolam BF could be imagined to be beneficial for all the patient populations 
mentioned above. Its use is not limited to phenotyping with microdoses, but it could be formulated as 
well to contain higher concentrations of midazolam. This would result in a pharmacologically active 
product with the same indication options as other midazolam-containing dosage forms. The buccal 
absorption of midazolam from such BF and rapid onset of action would favour its use in the fields of 
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epileptic seizures, sedation, induction of anaesthesia, or sleep disorders [176]. It remains to be tested 
what would be the maximal concentration of midazolam that could be loaded into a BF. Moreover, it 
needs to be investigated whether loading with higher amounts would influence the route of absorption 
due to limited buccal absorption capacity. Absorption could be a combination of buccal and intestinal, 
resulting in altered pharmacokinetic profiles compared to a microdosed midazolam BF. 
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3.4 ORAL DISINTEGRATING TABLETS BASED ON FUNCTIONALISED CALCIUM 
CARBONATE: A PALATABILITY STUDY IN CHILDREN 
It is well known that palatability is an important factor to be considered when developing oral 
formulations for children [300, 301]. In addition, swallowability is essential, especially for younger 
children [199]. Therefore, ODTs offer a very interesting alternative to conventional tablets or capsules. 
According to the FDA, ODTs are defined as “a solid dosage form containing medical substances, which 
disintegrates rapidly, usually within a matter of seconds, when placed upon the tongue. […] A large 
majority of these products have in vitro disintegrations times of approximately 30 seconds or 
less” [302]. 
 
3.4.1 IMPORTANT POINTS TO CONSIDER WHEN PERFORMING CLINICAL STUDIES WITH CHILDREN 
Among paediatric patients, the medication’s palatability is essential for patient acceptance, 
therapeutic compliance and successful outcome of a therapy [303, 304]. As outlined in chapter 1.4.2, 
medicine’s taste and the ability of children to swallow their medication may greatly influence the 
selection of a drug, therefore therapy, and prescribing practice. So far, there has not been much 
systematic methodological research on taste and mouthfeel evaluation of age-appropriate 
formulations in children. The study described above (chapter 2.4) was designed according to the 
special characteristics of paediatric patients [222].  
(I) The study procedure was kept as short as possible, lasting at maximum 30 minutes per volunteer in 
total. This included the informed consent procedure as well as explanation of the study, administration 
of the ODT, and palatability assessment and evaluation with children and parents. 
(II) It is important that the research personnel is well experienced in handling children to motivate 
them and to obtain honest answers and reactions from them. This requires close interactions with 
parents and caregivers to ensure study support from their side. Without their help it might be difficult 
to build the basis for fruitful interactions with the paediatric patients. Moreover, such support might 
be beneficial when it comes to interpreting facial expressions of the children and getting verbal 
answers from them. 
(III) To obtain verbal assent of a child and to make sure that it understood the procedure a child-
appropriate language is of paramount importance. This could be accompanied by leveraging cartoons 
to explain the procedure and showing the study product before administering it. For the ODT study it 
was important to explain to parents and children where to place the ODT and how to give feedback on 
its disintegration behaviour. 
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(IV) Since children are easily confused and become taste-fatigue by too many variables, it was decided 
to focus on taste acceptance and not to evaluate children’s preferences between several formulations. 
According to the recommendations by Sjövall and colleagues [223], exclusively verbal feedback 
regarding ODT acceptability was obtained from the younger sub-population. To increase objectivity of 
the results obtained from older children, an FHS and closed questions were additionally used. 
Moreover, they were asked for feedback on the disintegration time and behaviour of the FCC based 
ODTs. For both groups further information regarding acceptability of the tested ODT was obtained by 
seeking parental feedback. 
 
3.4.2 FUNCTIONALISED CALCIUM CARBONATE IS A SAFE EXCIPIENT FOR ODTS 
Functionalised Calcium Carbonate (FCC) consists of calcium carbonate and calcium phosphate, which 
are both considered to be non-toxic excipients and safe for paediatric use (chapter 2.4, [305]). Its 
unique and highly porous surface structure makes FCC well suited to prepare ODTs [225, 306]. 
Moreover, it was already used to formulate gastro-retentive drug delivery systems [307] as well as 
mucoadhesive particles for colonic drug delivery [308]. In accordance with their porous structure, FCC 
particles were successfully loaded with high amounts of different small molecule drugs (hydrophilic as 
well as lipophilic ones) and even proteins [308, 309]. In addition, the porous structure of FCC allows 
for rapid water uptake and fast disintegration upon contact with liquid, accelerating drug release of 
poorly water-soluble drugs [225, 308]. Therefore, FCC based ODTs offer very interesting options as 
safe, inert, and functional oral drug delivery systems.  
 
3.4.3 CAN OUR FCC BASED ODT BE CONSIDERED CHILD-APPROPRIATE? 
According to the criteria for paediatric medicines [208], the FCC based ODT was successfully tested in 
children in a clinical study. It can be considered a child-appropriate drug delivery device. 
(I) The FCC based ODTs presented in chapter 2.4 were designed as carrier tablets for drugs to be 
administered per os. As outlined above, FCC is a safe excipient and well suited for paediatric 
purposes [305].  
(II) Due to rapid disintegration of the ODT upon contact with saliva it does not need to be 
swallowed [225]. This makes FCC based ODTs highly acceptable for patients who have difficulties with 
swallowing solid dosage forms. In adults as well as in children palatability and acceptability of the 
tested ODT were rated as very positive and highly acceptable, respectively (chapter 2.4, [225]). Taste 
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masking was achieved by using artificial sweetener in combination with citric acid reacting with sodium 
bicarbonate. This results in a pleasant, sweet, and tickly feeling in the mouth. 
(III) For the different subgroups of the paediatric population dose adjustments can be easily achieved, 
since FCC is a very versatile multifunctional excipient. For this purpose, ODTs could be either 
formulated containing different amounts of active drug, or they could be compacted to large tablets 
or mini-tablets. The latter approach would permit dosing per kilogram of body weight without 
additional formulation work.  
(IV) Since ODTs can be put into the buccal pouch or directly onto the tongue, their administration even 
to very young children is easy and safe. Moreover, application of an ODT is highly accepted in almost 
every cultural background (in contrast to suppositories, for example). Such high acceptability of an 
easy-to-administer formulation increases patient compliance and lowers the risk for wrongly 
administered medications. 
 
3.4.4 ODTS APPROVED FOR PAEDIATRIC USE 
In Switzerland, there are several fused or dispersible tablets available on the market [310]. These 
include over the counter products as well as prescription drugs. Exclusively licensed for use in 
adolescents are: Abilify® (aripiprazole), a neuroleptic drug; Domperidon®/Neogast-X® LINGUAL 
(domperidone) against nausea and emesis; Felden® (piroxicam) to treat rheumatoid arthritis; and 
Temesta® Expidet (lorazepam) for sedation. Some of the products on the market are also approved for 
children: Co-Amoxi® (amoxicillin and clavulanic acid), an antibiotic drug; Dafalgan® ODIS 
(paracetamol), an analgesic and antipyretic substance; Fluimucil® lingual (acetylcysteine) to treat 
cough; Imodium® lingual (loperamide) against diarrhoea; Ondansetron® ODT (ondansetron) to treat 
chemotherapy-induced nausea and emesis; and Risperidon® oro (risperidone) for children with autism. 
In Switzerland, no orally disintegrating formulation for infants younger than 2 years is approved. 
Since FCC – the excipient investigated in the study described in chapter 2.4 – consists of two already 
well-known excipients [305], a safety assessment becomes much easier than for a completely novel 
substance, which should be introduced to the market. FCC based ready-to-use granules are already 
available (Omyapharm® ODG, [311]) and could serve as standard platform fulfilling the requirements 
in a PIP. The processes, which were implemented to produce the FCC based ODTs, were shown to be 
efficient and effective. Moreover, the resulting tablets were of high physical stability and easy to 
handle. Therefore, ODTs containing FCC as novel and safe excipient present a promising option to 
formulate child-appropriate medications in the future. 
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3.4.5 ODTS AND BFS 
BFs (chapters 1.3 and 2.3) as well as ODTs (chapters 1.4 and 2.4) are promising options to treat special 
and vulnerable patient populations. Both formulations can be easily administered to paediatric, 
elderly, or mentally disabled patients. As both formulations disintegrate rapidly upon contact with 
saliva there is no risk for suffocation upon swallowing, resulting in an improved safety profile. 
Moreover, direct contact of both formulations with the oral mucosa requires good taste-masking 
strategies, especially for bad-tasting drugs. ODTs and BFs can be formulated to offer well-accepted 
medications with good palatability. The latter is particularly important to be assessed carefully when 
designing an ODT, since particles from ODT disintegration could leave an unpleasant mouthfeel.  
Due to fast dissolution and absorption of loaded drugs a rapid onset of action can be expected. In 
addition, drug absorption within mouth, pharynx, or oesophagus through saliva increases 
bioavailability by avoiding first pass metabolism. Advantages of ODTs and BFs over liquid oral 
formulations include enhanced dosing accuracy as well as increased stability during storage and 
transport. Moreover, ODTs and BFs do not require special packaging, except for being protected from 
humidity. In terms of drug loading, ODTs might be beneficial compared to BFs, especially if ODTs are 
based on highly porous FCC [182, 183, 312, 313]. In conclusion, BFs as well as ODTs are worth to be 
further investigated to improve the medical options for vulnerable patient populations. Still their 
respective advantages and disadvantages might steer the decision more towards one or the other. 
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4 CONCLUSION 
 
 
Figure 9. The variety of drug delivery devices presented in this thesis. From development of polymeric vesicles 
for targeted drug delivery to hepatocytes (1), over a self-assembling chitosan hydrogel for wound healing (2) 
towards buccal films (BFs) for phenotyping (3) and oral disintegrating tablets (ODTs) as child-appropriate carrier 
formulations (4). 
 
In this work, a broad spectrum of different drug delivery systems was explained and evaluated 
(Figure 9). Nanoparticles, i.e. polymersomes, synthesised from the synthetic diblock copolymer 
PDMS-b-PMOXA were successfully characterised and modified. The targeting strategy towards 
hepatocytes included coupling of asialofetuin onto the polymersomes’ surface and proof of receptor-
mediated uptake via the ASGPR. Loading of a model drug into the polymersomes and its sustained 
release were achieved. In addition, all polymersomes variations were biocompatible in vitro as well as 
in vivo. However, preliminary results displayed that PMOXA was not capable of adding enough stealth 
properties to the polymersomes to avoid recognition by the MPS upon injection into zebrafish 
embryos. These results remain to be fully understood.  
The second polymeric drug delivery system being evaluated was a self-assembling chitosan hydrogel. 
Upon successful thiolation and modification with maleimide moieties, respectively, gelation started 
immediately after mixing aqueous solutions of these two polymers. The hydrogel revealed a porous 
structure, was able to imbibe excess of water and was biodegradable. Moreover, protein loading and 
release were achieved. Release properties were the same from freshly prepared as well as from 
lyophilised hydrogels. Spreadability of the self-assembling chitosan hydrogel was comparable to 
formulations that are already on the market. 
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These two formulations were mainly analysed in vitro. Within the last years, continuous progress was 
made regarding clinical application of targeted nanoparticles, e.g. in cancer therapy, and growth factor 
containing hydrogels to improve healing of chronic wounds. However, there is still a big gap from 
preclinical research to clinical studies and applications. 
Two more drug delivery systems were successfully tested in clinical settings. The buccal film (BF) 
containing microdoses of midazolam was successfully evaluated for phenotyping of CYP3A activity in 
healthy adults. Pharmacokinetic parameters such as AUC, Cmax, or metabolic ratios of midazolam and 
its main metabolite 1’-OH-midazolam were assessed and compared between application via BF and 
via a buccal reference solution (i.e. a diluted Dormicum® solution). It was shown that a microdosed BF 
could be an interesting novel diagnostic tool for phenotyping, especially of vulnerable populations such 
as children or geriatric patients. 
These patient groups might also benefit from the last drug delivery system presented in this thesis. 
Oral disintegrating tablets (ODTs) based on Functionalised Calcium Carbonate were tested for their 
palatability and disintegration behaviour in children from 2 to 10 years. These ODTs disintegrated 
within less 30 seconds, and children as well as their parents rated them as very convenient. Due to 
their good taste and mouth feeling they were highly accepted. Therefore, such ODTs could well serve 
as inert carrier for a broad variety of drugs, which – until now – do not exist in age-appropriate or good-
tasting formulations. 
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